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1. Introduction 
From single to multicellular organisms, protective mechanisms have evolved against 
endogenous and exogenous noxious stimuli. Over the past decades numerous signaling 
pathways by which the brain senses and reacts to such insults as neurotoxins, substrate 
deprivation and inflammation have been discovered. Research on preconditioning is aimed 
at understanding endogenous neuroprotection to boost it or to supplement its effectors 
therapeutically once damage to the brain has occurred, such as after stroke or brain trauma. 
Another goal of establishing preconditioning protocols is to induce endogenous 
neuroprotection in anticipation of incipient brain damage. Currently several endogenous 
neuroprotectants are being investigated in controlled clinical trials. There is consensus that 
many of the neuroprotectants, which were highly effective in animal models of stroke, but 
failed in clinical trials, were unsuccessful because of side effects, which in many cases led to 
premature termination of the trial. Nowadays research aims to overcome this problem by 
developing compounds which induce, mimic, or boost endogenous protective responses 
and thus do not interfere with physiological neurotransmission. In the present review we 
will give a short overview on the signals, sensors, transducers, and effectors of endogenous 
neuroprotection. We will first focus on common mechanisms, on which pathways of 
endogenous neuroprotection converge. We will then discuss various applications of 
endogenous neuroprotectors and explore the prospects of endogenous neuroprotective 
therapeutic approaches. 
2. Phisiopatology of cerebral ischemia  
Development of stroke prophylaxis involves the understanding of the mechanisms of 
damage following cerebral ischemia and elucidation of the endogenous mechanisms that 
combat further brain injury (FIGURE 1). 
The binding of glutamate to its receptors and the activation of voltage-gated Ca2+ channels 
(VGCC) causes calcium to influx into the cell. Calcium is among the mediators that initiate 
the genomic response to cerebral ischemia. The superoxide dismutase (SOD) gene is 
upregulated to neutralize the reactive oxygen species (ROS). The generation of nitrous oxide 
(NO) in the neuron is cytotoxic. The interaction between antiapoptotic genes, such as Bcl-2, 
and proapoptotic genes, such as Bax, determines whether cytochrome c will be translocated 
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from the mitochondria to the cytosol. In the cytosol, cytochrome c combines with Apaf-1 to 
activate the caspases. Proinflammatory cytokines, such as interleukin-1 (IL-1) and tumor 
necrosis factor-a (TNF-a), are generated. Survival pathways involving growth factors (GFs), 
immediate early genes (IEGs), and heat shock proteins (Hsps) are also stimulated. 
Ultimately, the activation of these genetic pathways determines the fate of the ischemic cell. 
 
  
Fig. 1. Phisiopatology of cerebral ischemia 
2.1 Excitotoxicity and calcium 
Although the brain represents only 2% of body weight, it uses an astonishing 20% of the 
body’s oxygen in adults. The innumerable cells of the brain require an almost continuous 
flow of oxygen and glucose, making them exquisitely sensitive to any interruption in energy 
supply. Energy depletion and reduced levels of adenosine triphosphate initiate a series of 
events that cause cells to die. Glutamate, the main excitatory neurotransmitter of the central 
nervous system, is a trigger of neuronal loss during stroke. During ischemia, an excess of 
glutamate is released into the extracellular space. The mechanism to clear glutamate is 
energy dependent; glutamate quickly builds to toxic levels when energy is depleted. 
Glutamate causes ionic shifts; Na+ enters the cell and K+ exits. Water passively follows the 
influx of Na+ leading to cellular swelling and edema. The membrane potential is lost and the 
cell depolarizes. In the ischemic core, cells undergo anoxic depolarization and never 
repolarize. However, cells in the penumbra initially retain the ability to repolarize so that 
they may depolarize again. As cells in the penumbra undergo these peri-infarct 
depolarizations the energy supply and ionic homeostasis are further compromised, resulting 
in an increase in the size of the ischemic lesion. Glutamate activates three main families of 
receptors: N-methyl-d-aspartate (NMDA), a-amino-3-hydroxy-5 methylisoxazole/kainate, 
and metabotropic glutamate receptors. Activation of these receptors leads to a buildup of 
Ca2+ within the cell. Ischemia therefore triggers glutamate receptor-mediated excitotoxicity 
and Ca2+ overload within the cell. Originally, neuronal death from excitotoxicity was 
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believed to result from depletion of cellular energy stores from overexcited neurons. 
However, the influx of Ca2+ seems to be the major pathogenic event contributing to cell 
death. This translocation of Ca2+ is accomplished through glutamate, particularly through 
the NMDA receptor, as well as through voltage-gated Ca2+ channels that open after cell 
depolarization. Calcium channel antagonists have displayed neural protection in animal 
models but have not shown benefit in clinical trials partially because they were administered 
too late after stroke onset or in insufficient quantity. However, it appears that Ca2+ influx 
into the cell is only the initial step in a complex biochemical cascade. 
2.2 Free radicals 
Reactive oxygen species are produced after the induction of ischemia and upon reperfusion. 
The oxidative stress produced by the reactive oxygen species destroys the cell through lipid 
peroxidation, protein oxidation, and DNA damage. Certain endogenous antioxidants 
scavenge and neutralize the reactive oxygen species. In particular, the antioxidant 
superoxide dismutase detoxifies the superoxide (O2-) free radical by converting it to 
hydrogen peroxide (H2O2). Glutathione peroxidase can then convert H2O2 into oxygen and 
water. During times of oxidative stress, the superoxide dismutase gene is upregulated. 
Neural protection strategies have included both the administration of exogenous superoxide 
dismutase and manipulation of the superoxide dismutase gene family. Nitric oxide (NO) is 
another free radical that is increased during ischemia due to an increase in intracellular Ca2+. 
The formation of NO is catalyzed by the enzyme NO synthase (NOS). NOS has several 
isoforms—a neuronal type (nNOS) located in neurons and an endothelial type (eNOS) in the 
vascular endothelium. NO is also generated in microglia, astrocytes and invading 
macrophages after the induction of an inducible isoform (iNOS). Initially after ischemia, the 
formation of NO in the vascular endothelium by eNOS may improve CBF through 
vasodilatation offering neuroprotection. However, synthesis of NO by nNOS and iNOS is 
cytotoxic, leading to an inhibition of mitochondrial respiration, glycolysis, and DNA 
synthesis. Because of the dual role of NO in cerebral ischemia, neuronal protection strategies 
need to target the specific isoform of NOS. For instance, deletion of the nNOS or iNOS gene 
in animal models has provided neuronal protection. 
2.3 Apoptosis 
After an ischemic event, cells in the penumbra may initiate a program of autodestruction 
known as apoptosis. Apoptosis occurs in the developing brain. More than half of progenitor 
neurons undergo this process of programmed cell death while forming neural circuits. 
During ischemia, cells in the ischemic core undergo necrosis while cells in the ischemic 
penumbra may actually self destruct through this process of apoptosis. The mitochondria is 
regarded as the apoptotic headquarters of the cell. One of the key events in apoptosis is the 
translocation of cytochrome c from the intermembrane of the mitochondria into the cytosol. 
In the cytosol, cytochrome c combines then with apoptotic activating factor (Apaf-1) to 
activate a set of proteases known as caspases. These caspases actually dismantle the cell 
during apoptosis. A family of death-promoting genes, known as the Bcl-2 family, 
determines whether a cell will undergo apoptosis. The Bcl-2 gene is antiapoptotic and 
prevents the translocation of cytochrome c and activation of caspases. However, the Bax 
gene (one of the members of the Bcl-2 family) is proapoptotic, facilitating the translocation 
of cytochrome c and apoptosis. During ischemia, proapoptotic genes such as Bax are 
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activated, resulting in the autodestruction of the cell. Thus, neuronal protection may be 
gained through blocking these death-promoting genes. Other strategies include giving 
caspase antagonists or preventing the translocation of cytochrome c from the mitochondria. 
Preventing apoptosis in the penumbra is another effective technique in animal models for 
neuronal protection. 
2.4 Inflammation 
The inflammatory response may be an important part of the ischemic cascade. Soon after the 
onset of stroke, leukocytes invade the ischemic zone. The mechanisms by which these 
inflammatory cells contribute to the evolution of ischemia include microvascular occlusion 
by adherence to the endothelium, producing cytotoxic enzymes and generating injurious 
free radicals. Cytokines are intracellular messengers that mediate the recruitment of the 
leukocytes and the induction of adhesion molecules. The two main proinflammatory 
cytokines are interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a). The adhesion 
molecules that facilitate the movement of leukocytes along the surface of the endothelium 
are the E and P selectins, whereas intracellular adhesion molecules attach the leukocytes to 
the endothelium so that they may leave the vascular space and enter the site of injury. 
Research has been focusing on the manipulation of these proinflammatory cytokines and 
adhesion molecules to provide neuronal protection.  
2.4.1 Survival pathways  
The cytokines that are activated during ischemia also include growth factors that actually 
promote neuronal survival and, in some cases, neuronal outgrowth and synapse formation. 
Fibroblast growth factor is the most extensively studied growth factor. Although the exact 
mechanism of neuroprotection of fibroblast growth factor is not fully understood, it includes 
upregulation of free radical scavenging enzymes and Ca2+ binding proteins, downregulation 
of the NMDA receptor and vasodilatation. The administration of growth factors has 
provided cerebral protection in animal models. Because they exert both protective and 
trophic influences on neurons, growth factors remain an exciting prospect in drug 
development for stroke. Other gene families and proteins are activated during ischemia. 
Immediate early genes, such as those of the Fos and Jun families, are activated soon after 
ischemia. It is believed that Ca2+ and reactive oxygen species are involved in the expression 
of immediate early genes. Although the exact role of each of the immediate early genes in 
ischemia is not yet understood, they are known to participate in apoptosis. Some immediate 
early genes may even afford neuronal protection. Ischemia also induces the expression of 
molecular chaperones known as heat shock proteins, which maintain protein function and 
assist in protein transport in response to injury. Increasing the expression of heat shock 
proteins to combat ischemia has been attempted.  
3. Erythropoietin 
The hormone erythropoietin (Epo) is a 165-amino acid (~30 kDa) glycoprotein that belongs 
to the cytokine type I superfamily. Originally, it was believed that the only role of Epo was 
the regulation of erythropoiesis. This role is attributed to the ability of Epo to inhibit 
programmed cell death (apoptosis) in erythroid cells and thus allow the maturation of 
erythrocytes. Since blood oxygen availability is the main regulator of erythropoiesis, 
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hypoxia induces the gene expression of Epo in the kidney, the main site for Epo production, 
and in the liver (Cotena et al, 2008) in a negative feedback system between the kidney and 
the bone marrow. Research performed in the last decade has shown that Epo and its 
receptor (EpoR) are expressed in tissues other than those involved in erythropoiesis. These 
include the brain, the reproductive tract (Kobayashi et al, 2002; Marti et al, 1996; Masuda et 
al, 2000), the lung, the spleen, and the heart (Fandrey and Bunn, 1993). Accordingly, a novel 
cytoprotective effect of Epo was established in several organs. For example, Epo reduced 
injury and dysfunction after ischemia-reperfusion in the mouse kidney (Patel et al, 2004), 
and it showed protection in various myocardial ischemia models (Bogoyevith,2004; Cai et al, 
2003; Parsa et al, 2003).  
3.1 Epo/EpoR expression and regulation 
Epo is mainly produced in the interstitial fibroblasts in the adult kidney and the hepatocytes 
of the fetus, whereas EpoR is normally expressed in erythroid precursor cells in the bone 
marrow (Marti, 2004). However, recent data have shown that the expression of Epo and its 
receptor, EpoR (both mRNA and protein), coincides in the same organ and even within the 
same cell. Epo and EpoR expression are widely distributed in the mammalian brain (Genc et 
al, 2004; Marti, 2004), albeit at lower levels than in the kidney (Brines and Cerami, 2005). Epo 
thus has to be added to the growing list of hematopoietic growth factors found to be 
expressed and act in the central nervous system (CNS). 
3.2 Expression of Epo/EpoR in the brain 
Epo/EpoR mRNA and protein were detected is several regions of the murine and primate 
brain, including cortex, hippocampus and amygdale, cerebellum, hypothalamus, and 
caudate nucleus (Siren et al, 2001). With respect to the type of cells in the brain that express 
Epo, astrocytes are the main source of Epo in the brain (Masuda et al, 1994). Moreover, it has 
been shown in vitro and in vivo that neurons express Epo (Bernaudin et al, 1999, 2000). 
Similarly, EpoR is expressed on neurons and astrocytes. In addition, primary cultures of 
human neurons, astrocytes, and microglia express EpoR mRNA (Nagai et al, 2001), and 
EpoR expression was also detected in primary cultures of rat oligodendrocytes (Genc et al, 
2006). In addition to neurons, oligodendrocytes, and glial cells, a strong immunoreactivity 
for EpoR was found to be associated with brain vascular endothelial cells, showing that 
these cells also express EpoR (Brines et al, 2000). These findings implicate a broad spectrum 
of actions of Epo in the brain. 
3.3 Regulation of Epo/EpoR expression 
As mentioned above, Epo is upregulated in response to hypoxia. As, for many of the 
hypoxic adaptation processes in the body, the regulation of Epo expression is based on the 
transcriptional regulation of two hypoxia-inducible factors HIF-1 and HIF-2 (Wenger, 2000). 
HIFs are heterodimers composed of an ǂ- and a ǃ -subunit. Two forms of the oxygen-labile 
ǂ exist, 1ǂ and 2ǂ. The ǂ-subunit is stabilized under hypoxic conditions leading to the 
binding of the heterodimer HIF-1 or HIF-2 to specific DNA sequences located in the hypoxia 
response elements of target genes such as Epo or vascular endothelial growth factor (VEGF) 
(Wenger, 2002). Although HIF-1ǂ was originally identified as the transcription factor 
responsible for Epo expression (Semenza et al, 1991), more recent evidence suggests that 
Epo is a target of HIF-2 (Eckardt and Kurtz, 2005). The stability of HIF-ǂ is regulated by 
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enzymatic hydroxylation of specific amino acids on the ǂ subunit by a group of oxygenases 
(FIGURE 2). Under normoxic conditions, a specific prolyl hydroxylation within the oxygen-
dependent degradation domain of HIF-ǂ takes place. This prolyl hydroxylation allows 
binding of the von Hippel-Lindau protein (pVHL), leading to ubiquitylation and 
proteasomal degradation of the HIF-ǂ subunit (Ivan et al, 2001; Jaakkola et al, 2001). The 
enzymes responsible for this hydroxylation are termed prolyl hydroxylase domain enzymes 
(PHD1-3) (Bruick and McKnight, 2001; Epstein et al, 2001) and are widely expressed. 
Furthermore, in the presence of oxygen, another hydroxylation reaction takes place on an 
asparaginyl group in the COOH-terminal transactivation domain of HIF-ǂ, blocking its 
binding to the transcriptional coactivators (Lando et al, 2002a). This process is governed by a 
specific asparaginyl hydroxylase termed factor-inhibiting HIF (FIH) (Hewitson et al, 2002; 
Lando et al, 2002b ). So, under normoxia, FIH and PHD(s) are active, leading to 
transcriptional inactivation and degradation of HIF-ǂ, whereas under hypoxic conditions 
both enzymes are inactive. HIF is then stabilized and able to induce the expression of target 
genes, including Epo. 
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Fig. 2. Under normoxic conditions, specific prolyl hydroxylation within the oxygen-
dependent degradation domain of HIF- ǂ takes place.  By contrast, under hypoxic 
conditions, FIH and PHD(s) are both inactive, and HIF is stabilized and able to induce the 
expression of target genes including Epo. 
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This basic mechanism of regulation seems to be of relevance for brain-expressed Epo, since 
in several experimental systems Epo was upregulated under hypoxic conditions in the brain 
of several mammalian species including mouse, rat, monkey, and human (Marti et al, 1996, 
2000; Siren et al, 2001). However, depending on the severity of hypoxia, Epo mRNA level 
can increase 3- to 20-fold in the brain in contrast to 200-fold in the kidney. Moreover, 
although the increase in Epo expression in the kidney seems to be transient with a decrease 
after 8 h of continuous hypoxia, the level of Epo in the brain remains high for at least 24 h 
(Chikuma et al, 2000). This indicates a tissue-specific degree of regulation. Indeed, although 
HIF-1ǂ levels in the kidney under systemic hypoxia peak after 1 h and again reach basal 
levels 4 h thereafter, in the brain the HIF-1ǂ peak level is reached after only 5 h and returns 
to the basal level not before 12 h (Stroka et al, 2001). A possible explanation for the different 
time course in the brain might be an altered composition of the various PHD forms. It has to 
be noted that hypoxia is not the only factor activating HIF. Several studies have shown that 
pro-inflammatory mediators such as tumor necrosis factor-ǂ (TNF-ǂ), interleukin-1ǃ (IL-1ǃ) 
or lipopolysaccharide (LPS) induce the expression of HIF (Frede et al, 2007). With regard to 
the EpoR, it is regulated by pro-inflammatory cytokines (Nagai et al, 2001), such as TNF-ǂ, 
IL-1ǃ, and Epo itself (Chin et al, 2000). The role of hypoxia in the regulation of EpoR 
expression is controversial. Whereas we did not observe hypoxic induction of EpoR 
expression in neurons or astrocytes (Bernaudin et al, 2000), anemic stress induced EpoR 
expression in the brain of human EpoR transgenic mice (Chin et al, 2000). Moreover, in the 
same study, hypoxia increased EpoR expression in neuronal cells in vitro. The mechanism of 
hypoxic EpoR regulation remains to be established, since EpoR has not been identified as 
HIF target gene so far. 
3.4 Epo signaling 
Epo promotes cell survival through inhibiting apoptosis (FIGURE 3).  
In erythroid cells, after binding of Epo to its receptor (EpoR), Janus tyrosine kinase 2 (JAK2) 
is phosphorylated and thus activated. This leads to engaging secondary signaling molecules 
such as signal transducer and activator of transcription 5 (STAT5), followed by the 
activation of Ras mitogen-activated protein kinase (MAPK), ERK-1/-2, and PI3K/Akt (22). 
Moreover, Epo induced the upregulation of the anti-apoptotic protein BCL-XL (Kilic et al, 
2005). The functional significance of these signaling molecules in erythropoiesis is not 
absolutely clear though. For instance, whereas in one study STAT5 knockout adult mice 
were largely unaffected in their erythroid lineage (Teglund et al, 1998), in another study 
STAT5 knockout embryos suffered from severe anemia, showed a reduced number of 
erythroid progenitors cells, and had higher numbers of apoptotic cells (Socolovsky et al, 
1999). Most of these pathways seem also to be functional in the brain (Brines and Cerami, 
2005; Kilic et al, 2005). In vitro, inhibition of MAPK and PI3K blocked Epo-mediated 
protection of rat hippocampal neurons against hypoxia (Siren et al, 2001b). Moreover, using 
ERK-1/-2 and Akt inhibitors, Kilic et al. showed that activation of these proteins is essential 
for Epo-mediated neuroprotection in an animal model of focal cerebral ischemia. The role of 
STAT5 in Epo-induced neuroprotection is, however, controversial. STAT5 phosphorylation 
has been shown to occur in hippocampal CA1 neurons after transient global cerebral 
ischemia in rats (Zhang et al, 2007). Therefore, the authors concluded that STAT5 plays a 
role in Epo-mediated neuroprotection. However, in a very recent study, in an in vitro model 
of glutamate toxicity using hippocampal neuronal culture from STAT5 knockout mouse 
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fetuses, STAT5 was not required for Epo-mediated neuroprotection (Byts et al, 2008). 
However, STAT5 was indispensable for the neurotrophic function of Epo. A unique 
pathway for the brain seems to be that activation of EpoR induces nuclear factor- κB (NF-κB) 
translocation into the nucleus and that this effect is important for Epo-mediated 
neuroprotection (Digicaylioglu and Lipton, 2001). Interestingly, Epo-induced NF-κB 
translocation was observed only in neuronal cells and not in astrocytes. Thus it appears 
likely that NF-κB, in the nucleus, induces the expression of neuroprotective and anti-
apoptotic proteins. However, some differences exist between the signaling cascade activated 
by Epo in the CNS and in erythroid cells. For instance, in one study, BCL-XL has been found 
to be important in Epo-mediated protection of erythroid but not neuronal cells (Rischer et al, 
2002). Additionally, Epo has been found to activate phospholipase C-gamma (PLCǄ) 
(Marreo et al, 1998) and thus can directly influence neuronal activity (Koshimura et al, 1999) 
and neurotransmitter release (Kawakami et al, 2000) by modulating intracellular calcium 
concentrations in neurons. 
 
 
Fig. 3. Epo Signaling 
3.5 Epo function in the CNS 
For almost a century, Epo was thought to be involved in the process of erythropoiesis only. 
Through its antiapoptotic action, it enables committed erythroid progenitor cells to survive 
and mature (Jelkmann, 1992). However, during the last decade, it became evident that Epo 
is implicated in other processes such as neuroprotection, neurogenesis, and angiogenesis, 
and plays an important role as neurotrophic as well as immunomodulatory factor. The 
important role of Epo in the CNS is also evident from studies with EpoR knockout mice. As 
a result of EpoR deficiency, these mice show massive apoptosis and a reduction in the 
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number of neuronal progenitor cells (Yu et al, 2002). A comprehensive description of the 
role of the Epo/EpoR system in development is found elsewhere (Arcasoy, 2008; Dame et al, 
2001). 
3.5.1 Neuroprotection 
For a long time, Epo has been used clinically in patients suffering from anemia due to end-
stage renal failure. In addition to the correction of anemia, these patients showed improved 
cognitive abilities (Siren and Ehrenreich, 2001). Initially, since it was believed that systemic 
Epo cannot pass through the blood-brain-barrier due to its large size (Recny et al, 1987) and 
brain-derived Epo production and expression of EpoR in the CNS were not yet discovered, 
the positive effect on cognition was attributed to the improved oxygen-carrying capacity of 
the blood after Epo-induced erythropoiesis. However, since later studies have shown that 
both Epo and its receptor are expressed in different regions of the brain by different cell 
types (Genc et al, 2004; Marti, 2004), the hypothesis was established that locally produced as 
well as exogenously added Epo could directly influence cognitive function. Interestingly, 
the expression level of Epo and EpoR is especially high in regions of the brain known to be 
particularly sensitive to acute hypoxia (Lipton, 1999), the hippocampus and the 
telencephalon (Digicaylioglu et al, 1995), suggesting that Epo might act as a protective agent 
against hypoxia. Indeed, infusion of soluble EpoR (capable of binding with endogenous 
EPO, thus sequestering it) into the brain of gerbils, which were subjected to a mild form of 
ischemia that normally does not cause neuronal damage, resulted in neuronal death in the 
hippocampus, clearly showing that endogenous Epo has a neuroprotective effect (Sakanaka 
et al, 1998). 
3.5.2 Neurotrophic function and neurogenesis 
Besides neuroprotection under hypoxic conditions, Epo also has a neurotrophic function in 
normoxic neurons. This was first demonstrated by Konishi and co-workers showing that 
Epo augments the activity of choline acetyltransferase in primary cultured mouse septal 
neurons (Konishi et al, 1993). Epo promoted the regeneration of septal cholinergic neurons 
in adult rats that had undergone fimbria-fornix transections. In addition and similar to its 
anti-apoptotic role in erythropoiesis, Epo promoted the survival and differentiation of 
dopaminergic precursor neurons in vitro (Studer et al, 2000). Moreover, hypoxia-induced 
Epo production appeared to directly act on neuronal stem cells in the forebrain, showing 
that Epo plays a direct role in neurogenesis after hypoxia (Shingo et al, 2001). In addition, 
Epo also acts indirectly by inducing brain-derived neurotrophic factor (BDNF) expression 
(Wang et al, 2004), which in turn augmented the effect of Epo on neurogenesis. These data 
show that Epo is not only involved in neuroprotection, but also in neuronal survival, 
differentiation, and neurogenesis. 
3.5.3 Angiogenesis and vascular permeability 
Besides its direct effects on neurons, Epo-induced neuroprotection may be attributed to an 
improvement in brain perfusion by promoting new vessel growth. Anagnostou et al 
demonstrated mitogenic and chemotactic effects of Epo on human umbilical vein and 
bovine adrenal capillary endothelial cells (Anagnostou et al, 1990). Moreover, Epo 
stimulated vessel outgrowth of rat aortic rings (Carlini et al, 1995), suggesting that Epo has 
angiogenic effects. This was further supported by the observation that Epo injection into the 
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mouse uterine cavity stimulated neovascularization in the endometrium (Yasuda et al, 
1998). Similarly, neovascularization was stimulated in the chick embryo chorioallantonic 
membrane upon Epo administration (Ribatti et al, 1999a). The angiogenic effect of Epo was 
also found in the brain, since capillary endothelial cells express two forms of EpoR mRNA 
and Epo showed a dose-dependent mitogenic activity on brain capillary endothelial cells 
(Yamaji et al, 1996). This angiogenic effect was finally confirmed in mice genetically 
engineered to lack either Epo or its receptor (EpoR) where mutant embryos suffer from 
severe defects in angiogenesis (Kertesz et al, 2004). In addition to its angiogenic effect, Epo is 
involved in the regulation of vascular permeability. In an in vitro model of the blood-brain 
barrier (BBB), Epo treatment protected bovine brain endothelial cells against VEGF-induced 
increase in vascular permeability (Martinez-Estrada et al, 2003). This suggests that the 
protective effect of Epo on the brain could be mediated by stimulating angiogenesis as well 
as by protecting the BBB. 
3.5.4 Anti-inflammation 
Inflammatory processes play a major role in the pathogenesis of cerebral ischemia, where 
Epo is protective. Inflammation results in influx of leukocytes from the blood into the brain 
and in activation of resident microglial cells (Dirnagl et al, 1999). These cells produce 
inflammatory mediators and cytokines leading to barrier damage, microvascular occlusion, 
and thus the aggravation of the injury (Witko-Sarsat et al, 2000). In an animal model of 
cerebral ischemia, administration of Epo resulted in the reduction of the local production of 
TNF, IL-6, and the chemokine MCP-1, all markers of inflammation, subsequently leading to 
a marked reduction of infarct size. These results indicate that Epo has an anti-inflammatory 
effect that contributes to its direct neuroprotective effect during cerebral ischemia (Villa et 
al, 2003). Since Epo did not reduce cytokine production in response to LPS applied directly 
in vivo and in vitro, the authors concluded that the observed antiinflammatory effect is due 
to inhibiting neuronal apoptosis and not to a direct effect on inflammatory cells. Epo might 
reduce leukocyte transmigration through endothelial cells, since Epo enhances the resistance 
of endothelial cells toward ischemia (Chong et al, 2002). The protective effect of Epo on 
oligodendrocytes against cytotoxicity induced by inflammatory stimuli (Genc et al, 2006) 
could explain the beneficial effect of Epo in case of MS where oligodendrocytes play a 
crucial role in the pathogenesis of the disease.  
3.5.5 Transport through BBB 
An important prerequisite for considering Epo as a therapeutic agent in CNS diseases is to 
answer the question as of whether Epo, administered systemically, is able to cross the BBB. 
Brines et al. (Brines et al, 2000) injected mice with biotinylated Epo and subsequently 
visualized brain section with peroxidase-labeled streptavidin. Indeed, a signal for biotin was 
detected in a region surrounding the capillaries extending into brain parenchyma. The 
authors concluded that Epo crosses the BBB. However, biotin might not be an ideal tool to 
study BBB permeability since it is rapidly transported across the BBB (Shi et al, 1993; Spector 
and Mock, 1987), and, therefore, even a small amount of free biotin in the blood will cross 
the BBB leading to false results. Since the authors detected EpoR in the brain capillaries, they 
attributed Epo transport through BBB to transcytosis. This hypothesis was later challenged 
by the observation that radiolabeled Epo and albumin crossed the BBB and entered the brain 
parenchyma in similar kinetics, showing that the transport of Epo across BBB is rather 
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mediated by the extracellular pathways (Banks et al, 2004). However, variations in 
physiological serum Epo level may not result in significant changes of Epo levels within the 
brain, since no correlation between serum and liquor Epo concentrations was found when 
the BBB is intact (Marti et al, 1997). In summary, one can conclude that endogenously 
produced Epo (by kidney or liver) has only a marginal influence on brain Epo availability, 
whereas high dosages of therapeutically administered r-hu Epo can penetrate even the 
intact BBB (Marti et al, 1997). Accordingly, many studies are currently ongoing to test the 
therapeutic potential of Epo in many CNS diseases. 
3.6 Epo in stroke 
The first hint came from the observation that the expression of Epo and its receptor in the 
brain is upregulated upon cerebral ischemia (Bernaudin et al, 1999; Siren et al, 2001). Several 
in vivo experiments confirmed this hypothesis. Intracerebroventricular injection of Epo 24 h 
before permanent occlusion of the MCA in mice reduced infarct volume significantly. 
Similarly, infusion of Epo in the lateral ventricles of gerbils in a global ischemia model 
rescued hippocampal CA1 neurons and increased the number of synapses in the same 
region (Sakanaka et al, 1998). Moreover, in another experimental rodent model of cerebral 
ischemia where the MCA is transiently occluded, systemic administration of Epo also 
reduced the infarct size (Brines et al, 2000). Significantly, this protective effect of Epo was 
retained even when Epo was applied 6 h after the onset of the cerebral ischemia. In addition, 
brain-specific overexpression of Epo reduced infarct size in mice subjected to transient 
cerebral ischemia (Kilic et al, 2005). Other studies, where the functional outcome of Epo 
treatment was investigated, have shown that Epo not only reduces infarct volume but also 
improves the learning ability in gerbils and reduces the navigation disability in rats 
(Sadamoto et al, 1998; Sakanaka et al, 1998). Epo has also been shown to be protective in 
models of hemorrhagic stroke where the interruption of the cerebral blood flow is due to 
subarachnoid or cerebral hemorrhage (Alafaci et al, 2000; Grasso et al, 2002). The above-
mentioned studies prompted the initiation of clinical trials in stroke patients. The safety and 
proof-of-concept phases of the Göttingen-Epo-Stroke Study have shown Epo to be safe and 
to improve the patient functional outcome after stroke (Ehrenreich et al, 2002). Although 
good evidence for direct neuroprotection exists, the observed brain-protective effect of Epo 
could also be attributed to its effect on astrocytes. Astrocytes protect neurons from oxidative 
stress by neutralizing reactive oxygen species (Dringen and Hirrlinger, 2003). It has been 
reported that activated astrocytes in ischemic human brain express increased levels of EpoR 
(Siren et al, 2001). Since Epo enhances brain glutathione peroxidase activity (Kumral et al, 
2005), Epo, by binding to EpoR on the surface of activated astrocytes, might contribute to the 
astrocyte-mediated neuroprotective effect against ischemia-induced free-radical formation. 
3.7 Safety concerns with the clinical use of EPO 
Clinical studies are ongoing to test the safety and efficacy of EPO for the treatment of 
different neurological diseases. In the recent multicenter Epo stroke trial (Ehreich et al, 
2009), adult stroke patients receiving Epo after tissue-plasminogen activator (t-PA)-induced 
thrombolysis reported increased mortality, intra-cerebral hemorrhage, brain edema, and 
thromboembolic events. The increased death rate in the rtPA population is still unexplained 
and may result from a combinant of factors and/or potential rtPA-EPO interactions. In 
contrast, in non rtPA population, the tendency toward a higher death rate in the EPO group 
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might be explained by higher stroke severity of dead patients on inclusion (before any study 
medication was applied). Moreover, the mechanism of action of EPO is different from the 
clot-dissolving strategy pursued by thrombolysis. It would, therefore, have been most 
attractive to see that the neuroprotective approach using EPO, aimed at salvaging 
potentially viable brain tissue from spreading of death signals, and thrombolysis, targeting 
reopening of the feeding artery, had provided additive beneficial outcome. However, the 
unexpected observation that a combination of EPO and rtPA is not advantageous, and can 
even be detrimental, poses at present a contraindication for acute EPO treatment in patients 
receiving rtPA. 
4. Albumin 
Albumin is the most abundant plasma protein synthesized mainly in the liver. Albumin is 
also a major component of most extracellular fluids including cerebrospinal fluid (CSF), 
interstitial fluid (ISF) and lymph. It is a non-glycosylated and negatively charged protein 
with high ligand binding and transport capacity. It has multifunctional properties which 
include the maintenance of colloid osmotic pressure of plasma, transportation of hormones, 
fatty acids, drugs and metabolites, regulation of microvascular permeability, antioxidant 
activity, anti-thrombotic activity and anti-inflammatory activity (Evans, 2002; Garcovich et 
al, 2009). Owing to its multifunctional properties it has been widely used in therapeutics 
related to hepatology. The volumeexpanding property of albumin, in combination with 
other therapeutic approaches, has been used for the clinical benefit of patients with liver 
cirrhosis. Also, human serum albumin (HSA) as an iso-oncotic (4-5%) solution has been 
used to combat blood volume deficits and as a hyperoncotic (20-25%) solution has been used 
for restoration of oncotic deficits (Arroyo, 2002; Garcovich et al, 2009). Albumin has been 
shown to play a crucial role in the microcirculation of many organs including brain. Owing 
to its strong hemodynamic and binding capacity, it has been implicated in physiological and 
many disease conditions of the brain. Albumin has been implicated in neurological diseases 
such as ischemic stroke, Alzheimer’s disease and epilepsy. High-dose human albumin is 
robustly neuroprotective in preclinical ischemia models and it is currently in Phase III 
clinical trials for acute ischemic stroke (Ginsberg, 2008). Albumin also has the potential to 
produce direct neuroprotective action on neuronal and glial cells.  
4.1 Albumin synthesis and distribution 
Albumin protein contains a single polypeptide chain of 585 amino acids with a molecular 
mass of approximately 67 kDa. 
In the mouse liver, the albumin gene becomes active during early foetal stages and the 
transcript levels gradually increase after birth until high levels are reached in the adult 
animal (Tilghman and Belayew, 1982). Albumin is synthesized as preproalbumin in the 
liver, which has an N-terminal peptide that is removed before the nascent protein is released 
from the rough endoplasmic reticulum. The product, proalbumin, is in turn cleaved in the 
Golgi vesicles to produce albumin. Albumin synthesis predominantly occurs in the liver at 
the rate of 10-15 g/day. In healthy human adults, total albumin content is approximately 
250-300 g/70 kg of the body weight and the majority of synthesized albumin (40-45 %) is 
maintained in the plasma. A very small amount of albumin is stored in liver ( < 2 g) and the 
remaining amount is located in the muscle and skin (Quinlan et al, 2005). Albumin synthesis 
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is regulated at both the transcriptional and post-transcriptional levels and this regulation is 
important to meet the demands of plasma, because albumin is not stored in the liver in large 
amounts. The rate of albumin transcription is affected by several conditions such as trauma, 
sepsis, hepatic diseases, diabetes and fasting. The change in interstitial colloid oncotic 
pressure is thought to be the predominant factor for regulation of albumin synthesis. 
Albumin homeostasis is maintained by balanced catabolism occurring in all tissues but most 
of the albumin (40-60 %) is degraded in the muscle and skin. However, the liver (15 %), 
kidney (10 %) and gastro-intestinal tract (10 %) are also responsible for albumin 
degradation. Albumin leaks from plasma at a rate of 5 % per hour and is returned to the 
vascular space at an equivalent rate through the lymphatic system. Albumin is also diffused 
into CSF and ISF compartments of the central nervous system (CNS) from blood circulation 
of the brain (Nicholson et al, 2000). Blood derived albumin in CSF and interstitial fluid (ISF 
is implicated in normal as well as many pathophysiological conditions of the brain. 
4.2 Albumin in the CSF 
CSF originates from choroid plexus in the ventricles. CSF flows through cisternae and 
subarachnoid space and finally drains through the arachnoid villi into venous blood. CSF 
has several important functions; it mainly helps to provide mechanical support for the brain. 
CSF also acts as a drainage pathway for the brain, by providing a ‘ sink ’ into which 
products of metabolism or synaptic activity are diluted and subsequently removed. Also, it 
acts as a route of communication within the CNS, i.e., it carries hormones, nutrients and 
transmitters between different areas of the brain. CSF albumin is predominantly a blood 
derived protein and it is mainly entered from the leptomeningeal blood CSF barrier (BCSFB) 
or from choroid plexus BCSFB (Johanson et al, 2008). The albumin quotient (Q alb ) in the 
CSF is approximately 30-80 % of the total protein. The altered Albumin CSF/serum ratio 
(QAlb) is the indicator of the dysfunction of the BCSFB. CSF serum Q alb, along with other 
blood derived proteins in CSF, is widely used in the diagnosis of neurological diseases 
(Reiber, 1998, 2003; Reiber and Peter, 2001). The exact role of albumin in CSF is not fully 
known, but it is proposed that albumin could be involved in the maintenance of CSF oncotic 
pressure, delivery of a wide range of molecules that are important for normal brain function 
and in the removal of some of the harmful molecules from the brain. The exact roles of 
albumin in CSF and in the brain function are not fully understood. However, many recent 
studies indicate that albumin might have a neuroprotective role via multiple mechanisms in 
different pathophysiological conditions.  
4.3 Albumin induced neuroprotection in experimental stroke 
Ischemic stroke is an acute cerebrovascular disease resulting from a transient or permanent 
reduction in the cerebral blood flow (CBF). It mainly occurs due to blockade of the major 
cerebral blood vessels by a local thrombus or an embolus. Ischemia causes reduction in the 
oxygen and nutrient supply to the brain areas which leads to neuronal cell damage or cell 
death. It can cause long-term disabilities such as muscle paralysis, cognitive deficits, 
language deficits, emotional deficits and even coma or death. Stroke is the third leading 
cause of death worldwide after coronary heart disease and cancer (Lloyd-Jones et al, 2009) 
and ischemic stroke comprises approximately 87 % of all types of brain strokes. The only 
approved treatment with intravenous fibrinolytic such as tissue plasminogen activator (tPA) 
within 3 h of stroke onset yields reperfusion and clinical benefits (rt -PA Stroke Study  
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Group, 1995; Hacke et al, 2004; Juttler et al, 2006). However, the goal is to discover a 
neuroprotective drug which can inhibit reperfusion injury and provide neuroprotection 
within a wide therapeutic window. Hemodilution is an old approach which has been 
investigated for many decades as a potential therapy for ischemic stroke. Infusion of dextran 
has been shown to increase CBF of both the normal and ischemic brain, either by decreasing 
blood viscosity or by vasodilation in response to diminished oxygen delivery (Wood and 
Kee, 1985; Korosue and Heros, 1992). Despite neuroprotective benefi ts in experimental set-
ups, several clinical trials of hemodilution in ischemic stroke have nonetheless proven 
negative or inconclusive (Scandinavian Stroke Study Group, 1987; Italian Acute Stroke 
Study Group, 1988; The Hemodilution in Stroke Study Group,1989). Subsequently, albumin 
has emerged as an alternative hemodiluting agent to dextran owing to its volume 
expanding properties (Sundt et al, 1967; Little et al, 1981; Emerson, 1989). However, only 
recently it has been rigorously evaluated for its anti-ischemic neuroprotective efficacy. 
Transient focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO) is 
the most widely used model to study molecular mechanisms of cerebral ischemia-
reperfusion injury and to screen neuroprotective drugs. It is less invasive with a low rate of 
mortality and a low coefficient of variation in lesion size (Longa et al, 1989; Belayev et al, 
1997b). In the rat MCAO model, Cole et al. reported that 5 % albumin administration at the 
onset of ischemia reduced ischemic brain injury as evidenced by reduced hematocrit, infarct 
volume and cerebral edema (Cole et al, 1990). In another study, administration of 
concentrated (20%) HSA (1% body weight, intravenously) to rats at the onset of recirculation 
induced substantial diminution of infarct volume together with a marked reduction of brain 
edema. Thus, it is proposed that albumin might modify water homeostasis and ultimately 
reduce edema of the ischemic brain (Belayev et al, 1997a). These two initial studies 
suggested that albumin therapy at the onset of ischemia or reperfusion induces 
neuroprotection.In a detailed study using magnetic resonance imaging, by means of 
diffusion-weighted magnetic resonance imaging (DWI), 25% Human Serum Albumin (HSA) 
solution (1% by body weight) administered immediately after reperfusion was associated 
with DWI normalization and a mitigation of pannecrotic changes within zones of residual 
injury at 24 h of injury. Albumin therapy lowered the hematocrit on average by 37% and 
raised plasma colloid oncotic pressure by 56%, improved the neurological score and 
reduced brain swelling throughout the 3-day survival period (Belayev et al, 1998). Similar 
treatment also improved local CBF as measured autoradiographically with 14C-
iodoantipyrine after 1 h of recirculation (Huh et al, 1998). Using laser scanning confocal 
microscopy and laser Doppler perfusion imaging, it was found that a beneficial effect of 
albumin therapy was attributed to reversal of stagnation, thrombosis and corpuscular 
adherence within cortical venules in the reperfusion phase after focal ischemia (Belayev et 
al, 2002). It was also reported that after 1 h of reperfusion, 1.25 g/kg intravenous HSA 
administration increased replenishment of polyunsaturated fatty acid (PUFA) lost from 
cellular membranes during ischemia (Rodriguez de Turco et al, 2002). These studies 
collectively indicate that albumin induced neuroprotection is attributed to properties such 
as reversal of thrombosis, improvement in microvascular blood perfusion, reduction in 
brain swelling and replenishment of PUFA in brain. All these actions could indicate that 
actions of albumin are confined in vascular space. However, it has been shown that 
treatment with human albumin following 2 h of MCAO also leads to albumin extravasations 
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and subsequently cellular uptake. It has been observed that cortical neurons with preserved 
structural features had taken up human albumin. Thus, it is reasonable to speculate that 
treatment with human albumin could also provide direct neuronal protection (Remmers et 
al, 1999). For the effective treatment of ischemic stroke, treatment should be started within a 
narrow therapeutic window of 3 h. Moderate-dose albumin therapy (1.25 g/kg 
intravenously) markedly provides neuroprotection even when treatment is delayed up to  
4 h after onset of ischemia (Belayev et al, 2001). Albumin treatment has also been found to 
be neuroprotective in other models of focal ischemia. Prompt albumin therapy improved 
neurological function and blood-brain barrier integrity after acute intracortical hematoma 
(ICH) (Belayev et al, 2005). In a model of laser-induced cortical arteriolar thrombosis, high-
dose albumin therapy induced a prompt, sustained improvement in microvascular 
hemodynamics distal to a cortical arteriolar thrombosis (Nimmagadda et al, 2008). In acute 
ischemic stroke, albumin combination therapy can attenuate the deleterious effects of tPA 
(Tang et al, 2009). Furthermore, albumin (1.25 g/kg) treatment maintains serum albumin at 
a higher level and attenuates cortex and hippocampus vascular endothelial growth factor 
(VEGF) expression at 6 h and 1 day after MCAO. This could partially contribute to the 
protective effects of albumin on reduction of brain edema and infarct size in the early stage 
of ischemia (Yao et al, 2010). The above mentioned studies prove that in experimental 
transient ischemia albumin provides neuroprotection via different indirect and direct 
mechanisms. Albumin has been found to be effective in other models of stroke such as 
permanent MCAO, global ischemia induced by bilateral common carotid occlusion (BCCO) 
and traumatic brain injury (TBI). In permanent MCAO, rats treated with 2 g/kg/day 
concentrated (25%) albumin begun after 30 min of ischemia showed diminished brain 
edema and infarct volume up to 6 days (Matsui et al, 1993). Furthermore, albumin (1.25 and 
2.5 g/kg) significantly reduced cortical and striatal infarct areas and increased cortical 
perfusion in the permanent ischemia model (Liu et al, 2001). In transient global ischemia, 
HSA-treated rats showed signifi cantly improved neurological deficits throughout a 7-day 
survival period along with increases in numbers of surviving CA1 hippocampal pyramidal 
neurons compared to saline-treated animals (Belayev et al, 1999b). In TBI, 15 min after 
trauma, HSA administration signifi cantly improved neurological defi cits and also 
significantly reduced total contusion area (Belayev et al, 1999a). These experimental trials 
altogether indicated significant neuroprotective roles of albumin in different models of 
ischemic stroke and encouraged the further development of this important molecule for 
possible treatment of ischemic stroke in humans. 
4.4 Albumin in clinical trials for ischemic stroke 
The Albumin In Acute Stroke (ALIAS) Pilot Clinical Trial was conducted during 2001 – 2005 
at two clinical sites (Universities of Calgary and Miami). This study was designed to 
investigate the safety and tolerability of albumin therapy in acute ischemic stroke. The 
ALIAS Pilot Clinical Trial used a multiple-tier, open-label, dose-escalation design. Human 
albumin (25%) in doses ranging up to 2.05 g/kg was well tolerated by patients with acute 
ischemic stroke without major dose-limiting complications. Concurrent tPA therapy did not 
affect the safety profile of albumin (Ginsberg et al, 2006a). Also, in this pilot trial the 
neuroprotective efficacy of albumin was evaluated and was found to be neuroprotective 
after ischemic stroke (Palesch et al, 2006). Based on the encouraging results of pilot trials of 
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albumin, the National Institutes of Health has funded a randomized multicenter placebo-
controlled effi cacy trial – the ALIAS Phase III Trial. A randomised, multicenter, double-
blind, placebo controlled trial (ALIAS Phase III Trial, www.clinicaltrials. gov; NCT00235495) 
is currently being conducted at approximately 70 clinical sites in North America (Ginsberg 
et al, 2006b; Hill et al, 2011).  
4.5 Direct neuroprotection by albumin: Mechanisms 
The neuroprotective mechanisms of albumin in ischemic stroke and AD are largely 
attributed to its hemodynamic properties and binding properties. However, in different in 
vitro systems, albumin has been reported to possess several direct neuroprotective actions. 
(Figure 4)  
Albumin could produce various neuroprotective actions in the intravascular compartment, 
cerebrospinal fluid-interstitial fluid compartment and intracellular compartment. 
HSA and its N-terminal tetrapeptide DAHK can block oxidant-driven cultured neuronal 
injury produced by hydrogen peroxide and copper/ascorbic acid (Gum et al, 2004). 
Furthermore, bovine serum albumin has been found to be neuroprotective by reducing both 
the DNA damage and apoptosis rates in cultured cortical neurons and these effects are 
probably due to its antioxidant activity (Baltanas et al, 2009). Albumin has been reported to 
play an important role in astrocyte functions. It is shown that albumin affects metabolism of 
cultured astrocytes (Tabernero et al, 1999). Albumin up on transcytosis into cultured 
astrocytes stimulates the synthesis of neurotrophic factor oleic acid which promotes 
neuronal differentiation (Tabernero et al, 2002). Megalin is a receptor for albumin in 
astrocytes and is required for the synthesis of the neurotrophic factor oleic acid (Bento -
Abreu et al, 2008). Also, this megalin induced albumin transcytosis and synthesis of  
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Fig. 4. Overview of possible neuroprotective mechanisms of albumin. 
www.intechopen.com
 
Endogenous Agents That Contribute to Generate or Prevent Ischemic Damage 
 
435 
neurotrophic factor is dependent on caveola and the adaptor protein cytosolic adaptor 
protein disabled (Dab-1) in cultured astrocytes (Bento -Abreu et al, 2009). These studies 
indicate that albumin could play a role in neuronal differentiation and development. 
Albumin also induces calcium mobilisation in cultured as well as brain astrocytes (Manning 
and Sontheimer, 1997; Nadal et al, 1998; Hooper et al, 2005). Albumin elicits calcium entry in 
the microglia which promotes proliferation of the microglia (Hooper et al, 2005). Astrocyte 
calcium signalling caused by albumin could have important physiological and 
pathophysiological consequences when the blood-brain barrier breaks down and allows 
albumin to enter the CNS. It is reported that albumin leakage induced by blood-brain 
barrier breaks is followed by albumin uptake into astrocytes which is responsible for 
epileptogenesis in rats (Ivens et al, 2007; van Vliet et al, 2007). Albumin causes 
downregulation of Kir current which results in the abnormal accumulation of [K+] o and 
consequent NMDA-receptor dependent pathological plasticity which isresponsible for 
epileptogenesis (Ivens et al, 2007). Recently, it was shown that albumin activates astrocytes 
and microglia producing infl ammatory responses via the mitogen-activated protein kinase 
pathway and these effects could be involved both in the mechanism of cellular injury and 
repair (Ralay Ranaivo and Wainwright, 2010). Altogether these fi ndings suggest that the 
majority of the effects of albumin on astrocytes, microglia and neuronal cells seem to be 
benefi cial; however, at augmented levels it could contribute towards astrocyte dysfunction. 
The direct effects of albumin on neuronal and glial cells necessitate further detailed 
investigation in individual pathological conditions. 
4.6 Endogenous albumin and neuroprotection: possible new paradigm 
Although albumin is mainly synthesized in the liver, mRNA expression level of albumin has 
been found in many non-hepatic rat tissues such as lungs, heart, kidney and pancreas, but 
not in the brain (Nahon et al, 1988). Also, non-hepatic albumin expression at the protein 
level is rarely confirmed. A recent study suggests that human brain microglia cells can 
express albumin both at mRNA and protein levels; furthermore, this expression is increased 
by amyloid beta (Aǃ) and lipopolysaccharide treatment (Ahn et al, 2008). It is suggested that 
enhanced levels of albumin and subsequent secretion by microglia could be implicated in A 
ǃ removal from the brain (Ahn et al, 2008). We have also found upregulation of albumin at 
both mRNA and protein levels in ischemic rat brain. Upregulation of albumin in ischemic 
brain could play a neuroprotective role against altered brain functions (Prajapati et al, 2010). 
These results indicate that de novo synthesis of albumin also occurs in the brain tissue. 
However, possible intracellular and extracellular neuroprotective actions of endogenously 
synthesized albumin is an unexplored area and warrants further investigations. 
5. Antithrombin III 
Antithrombin III (ATIII) is a single-chain glycoprotein in plasma and belongs to the family 
of the serpins. It is synthesized in liver parenchymal cells, and it plays a central role in 
regulating haemostasis. When bound to glycosaminoglycans, it is an important inhibitor of 
several serine protease, including factors Xa, IXa, XIa, and thrombin (Bauer and Rosenberg, 
1991), wich are involved in blood coagulation. Equimolar, irreversible complexes are formed 
between ATIII and the enzymes. Heparin and heparan sulfate glycoproteins (HSPGs) bind 
to multiple sites of the ATIII molecule resulting in a steric reconfiguration, thereby 
www.intechopen.com
 
Advances in the Preclinical Study of Ischemic Stroke 
 
436 
increasing the interaction between ATIII and the activated enzymes. It is believed that much 
of the physiological inactivation of enzymes by ATIII occurs in the endothelium, mediated 
by heparan sulfate (Figure 5) (Mammen, 1998). 
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Fig. 5. Role of heparan sulfate proteoglycan (HSPG) in inhibition of thrombin, in induction 
of prostacyclin, and inhibition of cytokine and tissue factor release from endothelial cells by 
antithrombin III. 
A large number of recent studies have shown that ATIII has anti-inflammatory actions, 
(Cuomo et al, 2007) which are independent of its effects on coagulation. These effects 
include the heterologous deactivation of activated leukocytes and the interaction with the 
endothelium, thereby reducing vessel wall transmigration and subsequent tissue and organ 
damage. Thus, ATIII may have two distinct and indipendent actions in patients with 
cerebral ischemia: (1) interference with pathologic coagulation, and (2) inhibition of 
inflammation. 
5.1 Effects of ATIII on abnormal coagulation 
The prothrombotic, proinflammatory state of stroke results in a promotion of thrombin 
formation and fibrin deposition at the vascular wall, as well as in the formetion of platelet-
leukocyte coaggregates, leading to severe disturbance of the microcirculation, capillary 
leakage and tissue damage (Piazza et al, 2010). Many of the events involved in this 
proinflammatory state have been shown to be inhibited by ATIII. The inhibition of factor Xa 
by ATIII may be particularly important for protection against, and treatment of, 
inflammation. This activated clotting factor has a number of proinflammatory effects, 
including stimulation if the production of IL-6, IL-8, MCP-1, E-selectin, and the soluble 
adhesion molecules ICAM-1 and vascular cell adhesion molecule (VCAM)-1, wich can be 
experimentally blocked by ATIII (Senden et al, 1998). The proinflammatory functions of 
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thrombin include stimulation of neutrophil/monocyte adhesion, action as a chemotactic 
factor for polymorphonuclear leukocytes (Esmon, 2000), and increased expression of the 
recently discovered inhibitor of fibrinolysis, thrombin-activable fibrinolysis inhibitor (TAFI) 
(Opal, 2000). Thrombin also stimulates the increased expression of IL-8 and plays an 
important role in ischemia-induced leukocyte rolling and adhesion (Kaur et al, 2001; 
Ludwicka-Bradley et al, 2000; Rabiet et al, 1994). Thus, the ability of ATIII to inhibit the 
actions of both factor Xa and thrombin gives it the potential to block, in part or fully, a wide 
range of proinflammatory events (Seegers, 1978). 
5.2 Coagulation-indipendent anti-inflammatory effects of ATIII 
In the late 1980s, initial publications reported on the property of ATIII to stimulate 
prostacyclin release from endothelial cells independent of thrombin interaction. Although 
some recent studies question such a mechanism, at least in vitro, a number of papers 
make an in vivo contribution of prostacyclin release as part of the ATIII anti-inflammatory 
properties likely (Uchiba and Okajima, 2001). Independent of ATIII's anticoagulatory 
activities at multiple points of action, a variety of studies provide evidence for a potent 
anti-inflammatory ATIII effect, wich can only be induced by high ATIII plasma activities 
in the range of 150%-200% (Harada et al, 1999; Hoffmann et al, 2000; Okajiama and 
Uchiba, 1998; Uchiba et al, 1996, 1998). These anti-inflammatory ATIII actions may be 
mainly mediated by an interaction of ATIII with the endothelium (Hoffmann et al, 2002), 
thereby producing a profound increase in endothelial prostacyclin production (Figure 5C) 
(Yamauchi et al, 1989). 
5.3 Effects of ATIII on leukocyte-endothelium interactions 
ATIII expresses the ability to inhibit leukocyte rolling and adhesion, wich are hallmarks of 
inflammatory reactions, and have explored the mechanisms underlying these effects. 
Ostrovsky et al (Ostrovsky et al, 1997) showed that ATIII administration significantly 
reduced neutrophil rolling and adhesion to pretreatment levels in a feline mesentery 
ischaemia-reperfusion model. Nevière et al (Nevière et al, 2001) and Hoffmann et al 
(Hoffmann et al, 2000) showed that the beneficial effects resulting from ATIII's blocking of 
leukocyte-endothelium interactions were eliminated when indomethacin, a cyclo-oxygenase 
inhibitor that blocks prostacyclin production, was added to the treatment. The 
administration of recombinant hirudin did not result in comparable beneficial effects, 
supporting the thrombin-indipendent mode of action of ATIII. As a consequence of the 
limited activated leukocyte-endothelium interaction, the severity of subsequent capillary 
leakage, disturbance of microcirculation, and organ damage were significantly reduced. A 
report by Yamashiro et al (Yamashiro et al, 2001) suggests direct affects of ATIII on 
leukocytes and endothelium by demonstrating the downmodulation of P-selectin by ATIII 
in the LPS-stimulated endothelium, thereby diminishing leukocyte rolling and subsequent 
transmigration. Support of this hypothesis has also been provided by the work of Souter et 
al (Souter et al, 2001) showing that the addition of ATIII to LPS-treated whole blood, 
HUVEC, and mononuclear cells inhibited production of both IL-6 and tissue factor; 
recombinant hirudin, a specific thrombin inhibitor, did not reduce the production of IL-6 or 
tissue factor, again suggesting that the observed inhibition by ATIII was not due solely to its 
ability ti inhibit thrombin (figure 5B and C). 
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5.4 Direct effect of ATIII on leukocytes 
Dunzendorfer et al (Dunzendorfer et al, 2000, 2001) have uncovered a second mechanism by 
which ATIII may inhibit neutrophil migration and adhesion to the endothelium; namely, 
heterologous deactivation of activated leukocytes by ATIII. These investigators noted that 
signaling in ATIII-induced neutrophil chemotaxis mimics an IL-8-induced response, ATIII 
inhibited migration of neutrophils towards IL-8, GRO-alpha, and fMLP; staurosporine, 
bisindolylmaleimide I, pertussis toxin, and an anti-CXCR1 monoclonal antibody all blocked 
ATIII-induced neutrophil chemotaxis. However, additional assays did not reveal binding of 
ATIII to CXCR1. Thus, the results of these studies are generally consistent with the 
conclusion that the effect of ATIII in neutrophil migration appear to involve a CXCR1-
related signaling pathway, its G-proteins, and protein kinase C. Recent findings have shown 
that the signalling pathway activated by ATIII in leukocytes are different in neutrophils, 
monocytes, and lymphocytes (Dunzendorfer et al, 2001; Kaneider et al, 2001, 2002). All 
togheter, these experiments led to the conclusion that ATIII in circulation protects 
leukocytes from premature activation. 
5.5 ATIII and nuclear factor-kappaB 
Oelschager et al (Oelshager et al, 2001) showed that ATIII produces a dose-dependent 
reduction in both LPS and tissue necrosis factor (TNF)-ǂ activation of nuclear factor-kappaB 
(NF-κB) in cultured monocytes and endothelial cells. Results reported by this working 
group and by Iampietro et al (Iampietro et al, 2000) indicate that these actions of ATIII block 
the increase in IL-6, IL-8, TNF, and tissue factor mRNA expression (figure 5B and C). 
Beyond control of coagulation, ATIII displays anti-inflammatory properties through an 
interaction with cells, reducing the synthesis and release of proinflammatory mediators, 
thereby modulating leukocyte activation and their interaction with the vessel wall. As a 
consequence, tissue damage and organ failure are reduced. 
6. Toll-like receptors 
The TLRs, so-called because of their homology to the Drosophila Toll receptor, were first 
characterized in mammals by their ability to recognize pathogen-associated molecular 
patterns such as those found in the bacterial cell wall components peptidoglycan (TLR2) and 
lipopolysaccharide (LPS) (TLR4), as well as viral dsRNA (TLR3), ssRNA (TLR7), and 
nonmethylated cytosine-guanine (CpG) DNA (TLR9). Recently it has been found that in 
addition to their role in pathogen detection and defense, TLRs act as sentinels of tissue 
damage and mediate inflammatory responses to aseptic tissue injury. Surfactant, HSP60, 
components of the extracellular matrix, and fibrinogen have all been shown to activate TLR4, 
while host HMGB1 and host mRNA and DNA are endogenous ligands of TLR2 (and TLR4), 
TLR3 and TLR9, respectively. TLRs, upon activation by either pathogen- or host-derived 
ligands, induce downstream signals that lead to cytokine and chemokine production and 
thereby initiate inflammatory responses. TLRs are located on antigen presenting cells such 
as B cells, dendritic cells, monocytes/macrophages and microglia. In addition, these 
receptors can be expressed by the cerebral endothelium and by cells within the brain 
parenchyma such as astrocytes, oligodendrocytes, and neurons (Bsibsi et al., 2002; Singh and 
Jiang, 2004; Jack et al., 2005; Bsibsi et al., 2006). The TLRs signal through common 
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intracellular pathways leading to transcription factor activation and the generation of 
cytokines and chemokines (Figure 6) (Vogel et al., 2003; Takeda and Akira, 2005). Each TLR 
family member, with the exception of TLR3, initiates intracellular signaling via recruitment 
of the intracellular Toll-interleukin 1 receptor (TIR)–domain-containing adaptor MyD88. 
When recruited to plasma membrane-associated TLRs, either directly (TLRs 5 and 11) or via 
the TIRAP adaptor (TLRs 1, 2, 4, 6), MyD88 enlists members of the IRAK family, including 
IRAK1, IRAK2, and IRAK4, to begin a process of auto- and cross-phosphorylation among 
the IRAK molecules. Once phosphorylated, IRAKs dissociate from MyD88 and bind TRAF6, 
an E3 ligase. TRAF6 in turn activates TAK1 which itself activates the IKK complex and 
MAPKKs. The IKK complex, composed of IKKǂ, IKKǃ and the regulatory subunit 
IKKǄ/NEMO, phosphorylates IκB proteins. This phosphorylation is necessary for the 
ubiquitination and proteosomal degradation of IκBs and the subsequent nuclear 
translocation of the transcription factor NFκB. Members of the MAPK family phosphorylate 
and activate components of the transcription factor AP-1. Together, these transcription 
factors induce inflammatory cytokine production (e.g. TNFǂ, IL1). MyD88 is also recruited 
to the endosomal receptors TLR7 and TLR9 again enlisting members of the IRAK family. 
Due to the endosomal location of the complex, the phosphorylated IRAKs are able to bind 
TRAF3 in addition to TRAF6. Activation of TRAF3 leads to phosphorylation, dimerization, 
and nuclear localization of the transcription factors IRF3, IRF5, and IRF7 with resultant type 
I interferon (IFN) production. Hence these endosomal TLRs are capable of signaling to 
NFκB, AP-1 and IRFs, resulting in a diverse genomic response. Endosomal TLR3 is unique 
among the TLRs because it does not signal through MyD88 but signals instead via 
recruitment of the Toll-interleukin 1 receptor domain-containing adaptor inducing 
interferon ǃ (TRIF). TRIF enlists the non-canonical IKKs, TBK1 and IKKε, which activate 
IRF3. Further, TRIF recruits TRAF6 and RIP-1, which results in activation of MAPK and 
IKKǂ/ǃ. Hence TLR3, like the other endosomal receptors, is capable of activating NFκB, AP-
1 and IRFs. Of all the TLRs, only TLR4 can recruit either MyD88 (via TIRAP) or TRIF (via 
TRAM) and can thus induce either the pro-inflammatory cytokines TNFǂ and IL1 via NFκB 
or the anti-viral IFNǃ via IRF3. The complement of TLR family members expressed by a cell 
depends on its identity and its activation status. Constitutive expression of TLRs within the 
brain occurs in microglia and astrocytes and is largely restricted to the circumventricular 
organs and meninges—areas with direct access to the circulation (Laflamme and Rivest, 
2001; Laflamme et al., 2001; Chakravarty and Herkenham, 2005). Human and murine 
microglia express TLRs 1–9 and generate cytokine profiles specifically tailored by the TLR 
stimulated (Bsibsi et al., 2002; Olson and Miller, 2004; Jack et al., 2005). Similarly, human and 
murine astrocytes express multiple TLRs, with particularly prominent TLR3 expression 
(Bsibsi et al., 2002, 2006; Carpentier et al., 2005; Jack et al., 2005; McKimmie and Fazakerley, 
2005). Microglia and astrocytes respond differently to specific TLR engagement reflective of 
their distinct roles in the brain. Microglia initiate robust cytokine and chemokine responses 
to stimulation of TLR2 (TNFǂ, IL-6, IL-10), TLR3 (TNFǂ, IL-6, IL-10, IL-12, CXCL-10, IFNǃ), 
and TLR4 (TNFǂ, IL-6, IL-10, CXCL-10, IFNǃ), yet astrocytes initiate only minor IL-6 
responses to all but TLR3 stimulation (Jack et al., 2005). Microglia express TLR3 and TLR4 at 
the cell surface while astrocytes express these receptors intracellularly (Bsibsi et al., 2002). 
The cellular location of TLRs affects their downstream signaling cascades (Kagan et al., 
2008), which may explain the different responses of these cells to TLR stimulation. The  
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Fig. 6. TLRs signaling 
inflammatory milieu also plays a critical role in regulating TLR expression. Microglia 
stimulated with CpG specifically up-regulate TLR9, whereas those stimulated with a 
synthetic TLR3 ligand suppress all TLRs except TLR3 (Olson and Miller, 2004). Similarly, 
astrocytes stimulated with LPS up-regulate TLRs 2 and 3 but suppress TLR4, while 
astrocytes exposed to RNA viruses up-regulate TLR3 and TLR9 (McKimmie and Fazakerley, 
2005). Thus microglia and astrocytes initiate a layered and multifaceted response to TLR 
engagement. Oligodendrocytes and endothelial cells express a relatively limited repertoire 
of TLRs. Oligodendrocytes express TLRs 2 and 3 (Bsibsi et al., 2002), while cerebral 
endothelial cells constitutively express TLRs 2, 4, and 9 (Constantin et al., 2004) and increase 
their expression of these TLRs in response to stressful stimuli, including systemic LPS and 
cerebral ischemia (Singh and Jiang, 2004; Zhou et al., 2007; Ziegler et al., 2007). In response 
to LPS, endothelial cells up-regulate E-selectin, an NFκB-dependent molecule, and IFNǃ, an 
IRF3-dependent molecule, indicating that these cells utilize the TLR–NFκB and the TLR–
IRF3 signaling pathways (Lloyd-Jones et al., 2008). Neurons express TLR3 and generate 
inflammatory cytokines (TNFǂ, IL-6), chemokines (CCL5, CXCL10) and antiviral molecules 
(IFNǃ) in response to dsRNA (Lafon et al., 2006; Prehaud et al., 2005). Neurons also employ 
TLRs in their development and differentiation. TLRs 3 and 8 are expressed on murine 
neurons early in development and inhibit neurite outgrowth in a MyD88- and NFκB-
independent manner (Ma et al., 2006). TLR2 and TLR4 have been found on adult neural 
progenitor cells where they appear to elicit opposing effects. While TLR2 activation 
stimulates neuronal differentiation of these cells, TLR4 activation decreases proliferation 
and neuronal differentiation, driving these cells toward an astrocytic fate (Rolls et al., 2007). 
Curiously, both TLRs exert these endogenous effects in a MyD88-dependent manner, 
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suggesting that these molecules utilize MyD88 in distinct ways. Hence even minor 
alterations of these fine-tuned endogenous pathways can have profound effects on cellular 
responses to TLR engagement. Studies with TLR knockout mice illustrate the endogenous 
function of TLRs in health and disease. TLR2 and TLR4 have been shown to play 
detrimental roles in the development of congestive heart failure and cardiac hypertrophy, 
respectively, by signaling through MyD88 and NFκB (Shishido et al., 2003; Ha et al., 2005). 
TLR2 has additionally been found to be proatherogenic in hyperlipidemic mice (Tobias and 
Curtiss, 2007), and TLR4 has been shown to produce inflammatory reactions in adipose 
tissue and thereby mediates obesity and insulin resistance (Tsukumo et al., 2007; Davis et al., 
2008). Conversely, TLR2 and TLR4 activation by hyaluronic acid protects lung tissue from 
non-infectious injury (Jiang et al., 2006), and TLR4 has been shown to help maintain lung 
integrity, and prevent the development of emphysema, by modulating oxidant generation 
(Zhang et al., 2006). The effects of endogenous TLR stimulation are clearly varied, 
depending on the cell and tissue type in which the receptors are found and on the disease 
process in which they are involved. The overwhelming and generally damaging 
inflammatory response of TLRs to aseptic tissue injury may be a consequence of TLR 
evolution in response to pathogens. In the setting of pathogen invasion, an inflammatory 
deluge may be the most effective means to clear microorganisms. The activation and influx 
of leukocytes, with the concomitant release of free radicals and tissue-destroying enzymes, 
assails not only the invading pathogen but any host cells that harbor the pathogen. 
However, when this same powerful response is co-opted by the host to clear and resolve 
tissue damage, it can destroy the very cells it is meant to save. This damage promoting 
characteristic is prominently observed following brain ischemia, where inflammation plays 
a critical role in both injury progression and resolution. 
6.1 TLRS and ischemic damage 
A significant portion of the damage associated with stroke injury is due to the resultant 
inflammatory response. This aspect of the innate immune response is exemplified by the fact 
that some anti-inflammatory strategies have been shown to ameliorate ischemic damage 
(Relton et al., 1996; Hara et al., 1997; Spera et al., 1998). The inflammatory 
response to stroke is initiated by the detection of injury associated molecules by local cells 
such as microglia and astrocytes. The response is further promoted by infiltrating 
neutrophils and macrophages, resulting in the production of inflammatory cytokines, 
proteolytic enzymes, and other cytotoxic mediators. In the mouse, leukocytes and brain cells 
(microglia, astrocytes and neurons) express TLRs (Zarember and Godowski, 2002; Olson 
and Miller, 2004). Hence, injury-associated molecules such as HSP60 and HMGB1 may act as 
endogenous ligands for TLRs, thereby initiating the damaging inflammatory response to 
stroke. It is increasingly clear that TLRs do in fact play a role in ischemic damage (Fig.). The 
pathogenic role of TLRs in ischemic processes was first demonstrated in a mouse model 
myocardial ischemia/reperfusion injury, because mice lacking functional TLR4 incur less 
damage than wild type mice (Oyama et al., 2004). Since then, TLR2 has also been shown to 
cause dysfunction following cardiac ischemia and both have been shown to exacerbate renal 
ischemic damage, in a MyD88-dependent and a MyD88-independent manner (Sakata et al., 
2007; Shigeoka et al., 2007). However, the particular pathway responsible for the damaging 
effects of TLR activation may differ depending on the cell type or organ affected as TLR4 
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worsens ischemic damage following liver transplant in a MyD88-independent, IRF3 
dependent fashion (Zhai et al., 2004; Shen et al., 2005). Importantly, TLR2 and TLR4 have 
been shown to play a role in cerebral ischemic damage. Mice lacking either functional TLR2 
or TLR4 are less susceptible to transient focal cerebral ischemia/reperfusion damage, 
demonstrating smaller infarcts than wild type controls (Cao et al., 2007; Lehnardt et al., 
2007; Ziegler et al., 2007). Further, mice lacking TLR4 incur less damage following global 
cerebral ischemia and permanent focal ischemia (Caso et al., 2007; Hua et al., 2007). The TLR 
endogenous ligands HSP 60, HSP70 and HMGB1 are found in the brain following injury 
(Kinouchi et al., 1993; Faraco et al., 2007; Lehnardt et al., 2008). Hence these molecules may 
activate TLR2 and TLR4 within the brain itself, leading to the generation of inflammatory 
mediators such as TNFǂ, IL1, IL6, and iNOS, all known to be associated with stroke 
damage. 
6.2 TLRS and neuroprotection 
In contrast to the detrimental role of TLRs in response to ischemia, stimulation of these 
receptors prior to ischemia provides robust neuroprotection. TLR4-induced tolerance to 
cerebral ischemia was first demonstrated with low dose systemic administration of LPS 
(endotoxin), a cell wall component of gram-negative bacteria, which caused spontaneously 
hypertensive rats to become tolerant to subsequent ischemic brain damage induced by 
middle cerebral artery occlusion (MCAO) (Tasaki et al., 1997). Since then, LPS-induced 
tolerance to brain ischemia has been demonstrated in a mouse model of stroke and in a 
porcine model of deep hypothermic circulatory arrest (Rosenzweig et al., 2004; Hickey et al., 
2007) (for additional information on the dual effects of neuro-immune crosstalk, please refer 
to Kerschensteiner et al., in this issue). Neuroprotection induced by LPS is time and dose 
dependent. Tolerance appears by 24 h after LPS administration and extends out to 7 days 
but is gone by 14 days (Rosenzweig et al., 2007). Protective doses of LPS appear to depend 
on the animal model of stroke and the route of systemic administration, ranging from 0.02–1 
mg/kg (Tasaki et al., 1997; Ahmed et al., 2000; Bordet et al., 2000; Furuya et al., 2005; Hickey 
et al., 2007; Kunz et al., 2007; Rosenzweig et al., 2007). Tolerance induction has been shown  
to require new protein synthesis and a modest inflammatory response, as it can be blocked 
by prior administration of cycloheximide or dexamethasone (Bordet et al., 2000). Specifically, 
TNFǂ has been implicated as a mediator of LPS-induced ischemic tolerance because 
inhibition of TNFǂ systemically (Tasaki et al., 1997) or within the brain (Rosenzweig et al., 
2007) blocks neuroprotection, and mice lacking TNFǂ fail to be protected by LPS 
preconditioning (Rosenzweig et al., 2007). In addition to its neuroprotective effects, LPS 
preconditioning has vasculoprotective efficacy. Nitric oxide appears to play a critical role in 
the protective effects of LPS. Mice lacking iNOS expression fail to be protected by LPS 
pretreatment (Kunz et al., 2007), and eNOS expression within the brain is directly correlated 
to the time window of LPS-induced neuroprotection (Furuya et al., 2005). LPS pretreatment 
has further been shown to prevent the impairment of endothelial and smooth muscle 
relaxation normally induced by ischemia/reperfusion injury (Bastide et al., 2003), resulting 
in normalization of cerebral blood flow in peri-infarct regions lasting out to 24 h after 
MCAO (Dawson et al., 1999; Furuya et al., 2005). LPS-induced ischemic protection requires 
an inflammatory response prior to the ischemic event, yet protection occurs through 
modulation of the inflammatory response following ischemia. Rosenzweig et al. (2004) have 
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shown that LPS preconditioning changes the response of circulating leukocytes to stroke, 
attenuating stroke-induced neutrophilia, lymphopenia, and monocyte activation. This 
altered inflammatory response extends into the brain itself. LPS preconditioning attenuates 
activation of microglia after stroke and reduces neutrophil infiltration into the ischemic 
hemisphere. Hence, LPS-induced preservation of microvascular function following MCAO 
may be due to suppressed lymphocyte adhesion to activated endothelium, either by TNFǂ-
induced suppression of endothelial activation and adhesion molecules (Ginis et al., 1999; 
Ahmed et al., 2000) or by prevention of cellular inflammatory responses to ischemia 
(Rosenzweig et al., 2004). One hallmark of LPS preconditioning is suppression of cytotoxic 
TNFǂ signaling following stroke. Mice that have been preconditioned with LPS prior to 
ischemia display a pronounced suppression of the TNFǂ pathway following stroke, as 
evinced by reduced TNFǂ in the serum, decreased levels of cellular TNFR1, and enhanced 
levels of neutralizing soluble-TNFR1. These mice are thus protected from the cytotoxic 
effects of TNFǂ after cerebral ischemia (Rosenzweig et al., 2007). Collectively, these 
mechanisms lead to a muted TNFǂ response to ischemic injury and increased cell survival. 
Recently a new TLR ligand has been shown to induce tolerance to brain ischemia. As with 
TLR4  and  L PS ,  s t imul a t ion  o f  TLR9  by  sys temic a l l y  ad mi nis tered  Cp G 
oligodeoxynucleotides induces robust protection against brain ischemia in a time and dose 
dependent manner. CpG pretreatment protects neurons in both in vivo and in vitro models 
of stroke (Stevens et al., 2008). Notably, the protection afforded by CpG depends on TNFǂ, 
as systemic CpG administration acutely and significantly increases serum TNFǂ, and TNFǂ 
knockout mice fail to be protected by CpG preconditioning. Similarities among the known 
TLR signaling pathways and their shared ability to induce TNFǂ, itself a potent 
preconditioning stimulus, suggest that stimulation of TLR4 and TLR9 may induce ischemic 
tolerance by similar means. The neuroprotective potential of other TLRs has yet to be 
explored, but this family of molecules may be a rich source of therapeutic targets. The 
finding that TLRs are mediators of ischemic injury provides insight into the potential 
mechanisms of LPS- and CpG-induced neuroprotection. In fact, TLR-induced tolerance to 
subsequent ischemia may occur by the same mechanisms that govern a very similar 
phenomenon—that of LPS-induced tolerance to subsequent LPS exposure. The latter 
phenomenon is known as “endotoxin tolerance” and occurs when pretreatment with a low 
dose of LPS renders cells or whole animals tolerant to the normally detrimental effects of a 
second, higher dose of LPS. Cells that are tolerant to LPS are defined by their inability to 
generate TNFǂ in response to TLR4 activation. Upon TLR4 ligation, LPS tolerant cells, 
unlike naive cells, do not recruit MyD88 to TLR4, and fail to activate IRAK-1 and NFκB 
(Medvedev et al., 2002). The TLR4–NFκB signaling axis becomes decommissioned following 
a primary exposure to LPS via an elaborate negative feedback loop that involves known 
inhibitors of TLR signaling. Among those inhibitors are Ship-1, which prevents TLR4-
MyD88 interaction, IRAK-M, a non-functional IRAK decoy, and TRIM30ǂ, which 
destabilized the TAK1 complex (Kobayashi et al., 2002; Sly et al., 2004; Shi et al., 2008). Thus, 
subsequent signaling of TLR4 to NFκB is blocked and inflammatory cytokine production is 
suppressed. Conversely, secondary exposure causes enhanced IFNǃ release, suggesting 
increased signaling via the TLR4-IRF3 axis (Broad et al., 2007). Thus, pretreatment with LPS 
causes cells to switch their transcriptional response to TLR4 stimulation by enhancing the 
IRF3- induced cytokine IFNǃ and suppressing the NFκB-induced cytokine TNFǂ. Similar to 
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endotoxin tolerance, priming TLR9 with its ligand, CpG, induces a state of hypo-
responsiveness to subsequent challenge with CpGs (Dalpke et al., 2005). Interestingly, cross-
tolerance between the two receptors has also been reported, as ligands for TLR9 induce 
tolerance against a subsequent challenge with a TLR4 ligand (Bagchi et al., 2007; Broad et al., 
2007). CpG-pretreated cells not only produce less TNFǂ when secondarily challenged with 
LPS, they also produce significantly higher levels of IFNǃ (Broad et al., 2007). Together, the 
aforementioned studies suggest the intriguing possibility that TLR stimulation prior to 
stroke may reprogram ischemia-induced TLR activation (Fig.). Specifically, administration 
of LPS or CpG may activate TLR4 and TLR9, respectively, causing a small inflammatory 
response, with an initial rise in TNFǂ. Cells would then regulate their inflammatory 
response through expression of negative feedback inhibitors of the TLR4–NFκB signaling 
axis that remain present when cells are subsequently exposed to endogenous TLR ligands 
generated from ischemia-injured tissue. Within this new cellular environment, stimulated 
TLRs such as TLR2 and TLR4 would be unable to activate NFκB-inducing pathways. 
Because of this, stroke-induced TLR2 signaling may be blocked completely leading to 
reduced injury, and stroke-induced TLR4 signaling would shift from NFκB induction to 
IRF3 induction (Fig.). Suppression of NFκB induction would be expected to protect the brain, 
as mice lacking the p50 subunit of NFκB suffer less cerebral ischemic damage than wild type 
mice (Schneider et al., 1999). Enhancement of IRF signaling would also be expected to 
protect the brain, as IFNǃ, a downstream product of IRF3 induction, has been shown to act 
as an acute neuroprotectant (Liu et al., 2002; Veldhuis et al., 2003a). IFNǃ, best known for its 
anti-viral effects, has potent anti-inflammatory activities as well. Several studies have shown 
that IFNǃ can stabilize the blood–brain barrier, potentially by reducing matrix 
metalloprotease production by activated glia (Veldhuis et al., 2003b; Kraus et al., 2004; 
Liuzzi et al., 2004). Similarly, it has been shown to inhibit monocyte migration across human 
brainderived endothelial cells (Seguin et al., 2003) and reduce cellular infiltration into 
damaged brain regions (Veldhuis et al., 2003b). On a cellular level, IFNǃ has been shown to 
reduce reactive oxygen species (Lopez-Collazo et al., 1998; Stewart et al., 1998; Hua et al., 
2002), suppress inflammatory cytokine production and induce IL-1Ra (Bosca et al., 2000; 
Palmer et al., 2004), promote nerve growth factor production by astrocytes (Boutros et al., 
1997) and protect neurons from toxicity induced by activated microglia (Jin et al., 2007). In 
addition, systemic administration of IFNǃ has been shown to reduce infarct damage in rat 
and rabbit models of ischemic stroke (Liu et al., 2002; Veldhuis et al., 2003a). Therefore, in 
the setting of LPS preconditioning, upregulation of this cytokine following stroke would be 
expected to contribute to neuroprotection. IFNǃ may not be the only neuroprotective 
molecule downstream of IRF signaling. TLR3 signals exclusively through the TRIF-
dependent pathway and stimulation of TLR3 in human astrocyte cultures induces the 
expression of several neuroprotective molecules such as brainderived neurotrophic factor, 
neurotrophin 4, pleiotrophin, and TGFǃ2 (Bsibsi et al., 2006), all of which have been 
implicated in endogenous neuroprotection (Yeh et al., 1998; Endres et al., 2000; Zhang et al., 
2005). Astrocytic TLR3 stimulation also results in production of the anti-inflammatory 
cytokine IL-10 (Bsibsi et al., 2006). Conditioned media from these cultures enhance neuronal 
survival and suppress astrocyte growth in slice cultures. Interestingly, LPS stimulation of 
macrophages has been shown to upregulate TLR3 expression (Nhu et al., 2006), inviting the 
possibility that LPS preconditioning may upregulate TLR3 in the brain, further enhancing 
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stroke-induced IRF signaling. We suggest that pretreatment with TLR ligands reprograms 
the brain’s response to ischemia and alters endogenous stroke-induced TLR signaling by 
suppression of the NFκB-inducing pathway and upregulation of the IRF-inducing pathway. 
Reprogramming causes a finely controlled shift in the balance of proinflammatory and 
antiinflammatory cytokines, and represents an endogenously orchestrated mechanism that 
protects the organism from additional damage. We further suggest that reprogramming of 
endogenous TLR signaling, with the subsequent generation of neuroprotective type I IFNs, 
is a unifying property of the neuroprotected phenotype. The brain has evolved numerous 
mechanisms that allow it to withstand the shortage of energy and the oxidative stress 
caused by ischemia. This tolerant state can be induced by prior exposure to LPS or CpG, or 
by prior exposure to other non-damaging (i.e. sub-threshold) noxious stimuli. For example, 
mild exposure to ischemia, excitotoxic stimuli, or inflammatory mediators can precondition 
the brain to better tolerate a subsequent injurious ischemic event. These mild 
preconditioning exposures herald impending danger and, as such, induce endogenous 
protective strategies in anticipation of injury. Though the final outcome of tolerance 
induction is the same—protection of brain tissue from ischemic injury—the effector 
mechanisms employed by the brain are as diverse as the preconditioning stimuli that 
induced them. In fact, the phenotype of neuroprotection may be specifically tailored by the 
nature of the preconditioning stimulus (Stenzel-Poore et al., 2007). For example, 
preconditioning events that deprive the brain of oxygen or glucose for a short time lead to 
conservation of energy regulation and mitochondrial integrity during the injurious ischemic 
episode (Stenzel-Poore et al., 2003; McFalls et al., 2006). Further, as we have described above, 
preconditioning events that invoke a small inflammatory response lead to altered 
inflammatory responses to damaging ischemia (Rosenzweig et al., 2004, 2007). It should be 
emphasized that although significant overlap exists in the cellular processes induced by 
these diverse stimuli, the pathways that dominate each response are distinct. The first 
demonstration that a short period of oxygen deprivation could protect the brain from a 
subsequent extended period of hypoxia occurred in 1943 (Noble, 1943). Since then, 
hundreds of studies have been undertaken to better understand the underlying mechanisms  
of “ischemic preconditioning.” Though several endogenously protective pathways are 
induced by the initiating ischemic event, one particular theme is emerging—that of 
mitochondrial maintenance and energy conservation (Dirnagl and Meisel, 2008). The 
priming ischemic episode appears to induce cellular pathways that protect mitochondria 
against stroke induced deficits in the electron transport chain (Dave et al., 2001). These 
pathways protect mitochondrial membrane potential (Wu et al., 2004), preserve 
mitochondrial cytochrome c (Zhan et al., 2002), increase mitochondrial sequestration of Ca+ 
and increase Ca+-ATPase activity. In addition, ischemic preconditioning appears to suppress 
molecules that regulate ion channels, leading to channel arrest—i.e. reduction in ion 
permeability through the plasma membrane—which has been shown to reduce the amount 
of ATP required to maintain ionic homeostasis (Buck and Hochachka, 1993; Stenzel-Poore et 
al., 2003). Finally, a decrease in the overall cellular metabolic rate limits the stressful effects 
of oxygen deprivation. The pre preconditioning stimulus suppresses the expression of genes 
involved in protein turnover, proteasomal degradation, and energy metabolism (Stenzel-
Poore et al., 2003). Although ischemic preconditioning has also been shown to help maintain 
protein structure and function and to suppress the damaging inflammatory response to 
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stroke, it is increasingly clear that sustaining mitochondrial integrity and conserving energy 
are important mechanisms driving endogenous ischemic tolerance. Several studies have 
shown that the priming ischemic event induces HSP70 within the brain (Truettner et al., 
2002). In addition to its role in stabilizing protein structure, HSP70 acts as an endogenous 
ligand of TLR4. In fact, extracellular HSP70 has been shown to induce endotoxin tolerance 
(Aneja et al., 2006). Hence TLRs may be stimulated in the course of ischemic 
preconditioning, resulting in a reprogrammed TLR response to subsequent injurious 
ischemia. One of the molecular consequences of reprogrammed TLR signaling is an increase 
in IFNǃ. Notably, IFNǃ has been shown to aid in the maintenance of mitochondrial 
integrity. For example, treatment of astrocytes with IFNǃ prevents neuronal mitochondrial 
respiratory chain damage (Stewart et al., 1998) and reduce IFNǃ induced nitric oxide 
synthase (Stewart et al., 1997). Thus reprogrammed TLR signaling may help shape the 
phenotype of ischemia-induced tolerance The phenomenon of inflammation-induced cross-
tolerance to ischemia is not limited to LPS, but extends to TNFǂ as well. Nawashiro et al. 
(1997) were the first to demonstrate that intracisternal administration of TNFǂ protects the 
brain from subsequent ischemic challenge. This protection is correlated to a decrease in 
CD11b immunoreactivity, suggesting a decrease in the inflammatory response to ischemia 
in the setting of preconditioning. Consistent with this observation, TNFǂ pretreatment of 
astrocytes and endothelial cells, through its signaling intermediate ceramide, produces a 
state of hypo-responsiveness as pretreated cells fail to upregulate ICAM-1 during 
subsequent hypoxia (Ginis et al., 2002). The decrease in ICAM-1 does not reflect global 
cellular suppression, but instead signifies a reprogrammed genomic response to stroke, as 
the hypoxiainduced expression of cytoprotective MnSOD is not affected by preconditioning. 
Evidence for a reprogrammed genomic response to ischemia is supported by the 
observation that TNFǂ preconditioning prevents hypoxia-induced phosphorylation of the 
proinflammatory transcription factor component NFκBp65, thereby preventing its 
interaction with the transcriptional activator p300. Taken together, these data indicate that 
pretreatment with TNFǂ reprograms the cellular environment and hence alters 
inflammatory reactions in response to ischemia. Just as TNFǂ can induce tolerance to 
subsequent ischemic exposure, it can induce tolerance to subsequent LPS exposure (Porter et 
al., 1998; Ferlito et al., 2001; Murphey and Traber, 2001). Hence TNFǂ preconditioning has 
the potential to induce a state of cross-tolerance to TLR ligands, and thereby reprogram the 
TLR response to stroke. IFNǃ has been shown to cause many of the effects observed in 
TNFǂ-induced ischemic tolerance, such as suppression of inflammatory cytokine 
production, including TNFǂ itself, and reduction of cellular infiltration into ischemic brain 
regions (Veldhuis et al., 2003a). Together, these studies suggest that multiple 
preconditioning stimuli may cause a reprogrammed TLR response to stroke. IFNǃ, 
produced secondary to this reprogrammed response, may aid in maintaining mitochondrial 
stability and in dampening the inflammatory responses to injurious ischemia. 
7. The receptor for Advanced Glycation End Products (RAGE) 
Advanced glycation end products (AGEs) are nonenzymatical adducts of proteins, lipids, 
and nucleic acids which form in a time-dependent manner in a pro-oxidant environment, 
especially when target molecules turnover slowly and the level of aldoses is elevated 
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(Schmidt et al, 1995; Vlassara et al, 1994; Bierhaus et al, 1998; Baynes, 2003; Thornalley, 1998; 
Brownlee, 2000). Glycation of macromolecules was originally thought to mark senescent 
proteins for subsequent degradation by macrophages. Receptors binding AGEs were 
regarded as scavenger receptors involved in AGE disposal and cell regeneration, and 
defective clearance of such modified proteins was believed to be important in aging and 
diseases with accelerated AGE-formation, such as diabetes or atherosclerosis (Vlassara et 
al,1994, 1985). However, when the receptor for AGEs (RAGE) was cloned and first 
characterized (Neeper et al,1992; Schmidt et al,1992, 1994) it turned out that binding of 
AGEs to RAGE did not accelerate their clearance and degradation. Rather, ligand–receptor 
interaction induced sustained post-receptor signaling, including activation of p21ras, MAP 
kinases, and the NF-κB pathway (Lander et al, 1997; Basta et al, 2002; Bucciarelli et al, 2002). 
Thus, the concept of RAGE as a scavenger/clearance receptor has to be revised and 
extended.  
7.1 RAGE: Structure and ligand recognition 
RAGE is a member of the immunoglobulin superfamily of cell surface molecules (Schmidt 
et al, 1993; Sugaya, 1994). The gene is localized on chromosome 6 near the HLA locus in 
the vicinity of the MHCIII complex in humans and mice, in close proximity to the 
homeobox gene HOX12 and the human counterpart of the mouse mammary tumor gene 
int-3 (Malherbe et al, 1999). The receptor is composed of three immunoglobulin-like 
regions: one “V”- type domain and two “C”-type-domains, a short transmembrane 
domain, and a 43-amino acid cytoplasmic tail (Neeper et al, 1992; Schmidt et al, 1994; 
Lander et al, 1997). While the “V-type” domain confers ligand binding, the cytoplasmic 
tail is critical for intracellular signaling. Shortly after RAGE was recognized as a receptor 
for AGEs, it became evident that a number of other ligands also interacted with the 
receptor (Bucciarelli et al, 2002; Schmidt et al, 2001; Du Yan et al, 1997; Yan et al, 1996, 
2000). Structural analysis of ligand–RAGE interaction revealed that the receptor 
recognized three-dimensional structures, such as ǃ-sheets and fibrils, rather than specific 
amino acid sequences (i.e., primary structure) (Bucciarelli et al, 2002; Schmidt et al, 2001). 
In addition to AGEs, RAGE binds amyloid-ǃ peptide (accumulating in Alzheimer’s 
disease) (Du Yan et al, 1997; Yan et al, 2000) and amyloid A (accumulating in systemic 
amyloidosis). Further, ligands of RAGE are S100/calgranulins, a family of closely related 
calcium-binding polypeptides that accumulate extracellularly at sites of chronic 
inflammation (Hofmann et al, 1999; Marenholz et al, 2004). Another proinflammatory 
ligand of RAGE is the DNA binding protein HMGB1 (amphoterin), which is released by 
cells undergoing necrosis (Hori et al, 1995; Wang et al, 1999; Anderson and Tracey, 2003; 
Treutiger et al, 2003). Besides binding ligands actively participating in chronic 
inflammatory and immune responses, RAGE also interacts with surface molecules on 
bacteria (Chapman et al, 2002), prions (Sasaki et al, 2002), and leukocytes (Chavakis et al, 
2003). Thus, RAGE is much more than a receptor for AGEs; it has a broad repertoire of 
ligands, which share the propensity to accumulate in tissues during aging, chronic 
degenerative diseases, inflammation and the host response (Tretiger et al,2003). Therefore, 
RAGE should be considered a pattern recognition receptor (PRR) (Schmidt et al, 2001; 
Chavakis et al, 2003; Liliensiek et al, 2004; Gordon, 2002), and potential similarities to 
members of the family of Toll-like receptors should be considered (Akira et al, 2001).  
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7.2 RAGE-mediated NF-κB activation 
Engagement of RAGE results in intracellular signaling which leads to activation of the 
proinflammatory transcription factor NF-κB, the latter rapidly activated as part of the first 
line of cellular defense (Bierhaus et al, 2001). In resting cells, NF-κB resides in the cytoplasm 
in its inactive form bound to the inhibitor molecule IκBǂ (Barnes and Karin, 1997). Upon 
activation, IκBǂ is rapidly phosphorylated and degraded, resulting in release and 
translocation of NF-κB (preferentially the NF-κB-heterodimer p50/p65) into the nucleus. 
Subsequent to nuclear translocation, NF-κB binds to decameric DNA sequences and 
activates transcription of NF-κB regulated target genes, such as cytokines, adhesion 
molecules, prothrombotic and vasoconstrictive gene products, RAGE itself, and IκBǂ 
(Barnes and Karin, 1997; Li and Schmidt, 1997; Bierhaus et al, 2000). A number of anti-
apoptotic genes, including Bcl-XL, Bcl-2, and the Bcl-2 homologues A1, are also under 
control of NF-κB. NF-κB activation therefore provides a rapid and sensitive cellular 
response in the absence of new protein synthesis, which promotes cellular survival. One 
unique feature of RAGE-mediated NF-κB activation is the prolonged time course which 
appears to overwhelm endogenous autoregulatory feedback inhibition loops (Bierhaus et al, 
2001). NF-κB activation subsequent to ligation of RAGE is initiated by the degradation of 
IκBǂ and IκBǃ, followed by new synthesis of NF-κBp65 in the presence of newly 
synthesized IκBǃ. De novo synthesis of p65 mRNA results in a constantly growing pool of 
excess transcriptionally active NF-κBp65. In contrast, the amount of newly synthesized IκBǂ 
is not sufficient to retain NF-κBp65 in the cytoplasm. In addition, newly synthesized IκBǃ 
has been shown to be hyperphosphorylated, thereby sequestering newly synthesized NF-κB 
from IκBǂ (Thompson et al, 1995; Johnson et al, 1996)? Thus, new synthesis of IκBǃ might 
further promote RAGEdependent sustained NF-κB activation. Since, in turn, RAGE 
expression is induced by NF-κB (Li and Schmidt, 1997), sustained activation of NF-κB 
results in upregulation of the receptor and further ensures maintenance and amplification of 
the signal.  
7.3 AGEs and RAGE affect cellular defense mechanisms 
Besides activating proinflammatory responses, RAGE downregulates cellular defense 
mechanisms. Ligation of RAGE by AGEs results in the suppression of reduced glutathione 
(GSH) and ascorbic acid levels and thereby contributes to increased intracellular oxidant 
stress (Lander et al, 1997; Bierhaus et al, 1997). Depletion of glutathione accounts for 
diminished glyoxalase-1 recycling and decreased in situ activity of glyoxalase-1 
(Thornalley,1998). Glyoxalase-1, in turn, is required to catalyze the conversion of reactive, 
acyclic alpha-oxoaldehydes into the corresponding alpha-hydroxyacids (Degenhard 1998; 
Thornalley et al,1999). Since alpha-oxoaldehydes, such as methylglyoxal, represent the 
largest pool of reactive intracellular AGEs, glyoxalase-1 has an important role in reduction 
of the cellular AGE load. Consistent with this concept, in vitro experiments with cultivated 
endothelial cells have demonstrated that glyoxalase-1 overexpression prevents intracellular 
AGE formation (Shinohara et al,1998). Studies in the model organism Caenorhabditis 
elegans have recently confirmed that overexpression of glyoxalase-1 not only prevents AGE 
formation, but also protects the animals from deleterious effects of oxidant stress, as 
evidenced by increased longevity (Morcos et al,2004). These observations imply that 
engagement of RAGE not only results in increased cellular activation, but also in reduction 
of AGE detoxifying mechanisms.  
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7.4 RAGE and neuroprotection 
RAGE transcription is controlled by several transcription factors, including SP-1, AP-2, NF-
κB, and NF-IL6 (Li and Schmidt, 1997). RAGE expression occurs in both a constitutive and 
inducible manner, depending on the cell type and developmental stage (Hori et al,1995; 
Brett et al,1993). Whereas RAGE is constitutively expressed during embryonic development, 
its expression is downregulated in adult life. However, known exceptions are skin and lung, 
which constitutively express RAGE throughout life. Most other cells, including 
monocytes/macrophages, endothelial cells, smooth musclecells, fibroblasts, and neuronal 
cells, do not express significant amounts of RAGE under physiological conditions but can be 
induced to express RAGE in situations where either ligands accumulate and/or 
transcription factors regulating RAGE are activated (Basta et al, 2002; Bucciarelli et al, 2002; 
Hanford et al, 2004; Akira et al, 2001; Li et al,2004; Sorci et al, 2004a, 2004b; Cortizo et al, 
2003; Shanmugam et al, 2003; Ishihara et al, 2003). Due to its ability to sustain cellular 
activation, RAGE has the potential to function as a master switch capable of converting a 
transient proinflammatory response, evoked by an inflammatory stimulus into sustained 
cellular dysfunction (Schmidt et al, 2001; Bierhaus et al, 2001). The majority of cellular 
stressors induce both the formation of reactive oxygen species (ROS) and transient 
activation of NF-κB (Yeh et al, 2001; Taguchi et al, 2000; Huttunen et al, 19999; Huang et al, 
2001; Wautier et al, 2001). In addition, inflammatory cells directly release RAGE ligands, 
such as S100/calgranulins and HMGB-1 (Kokkola et al, 2005). The myeloperoxidase system 
of human phagocytes generates N" -(carboxymethyl)lysine, a highly reactive AGE and 
RAGE-ligand, at sites of inflammation (Anderson et al, 1999; Kislinger et al, 1999). High 
glucose concentrations promote AGE formation inside and outside cells (Brownlee, 2000; 
Schiekofer et al, 2003). Such time-dependent formation of AGE might also play a role in the 
expression of binding sites for amyloid peptides (Yan et al, 2000). In turn, RAGE has been 
shown to mediate transport of pathophysiologically relevant concentrations of amyloid-ǃ 
peptide into the CNS (Mackic et al, 1998). Thus, stimuli initially inducing oxidant stress and 
NF-κB activation have the potential to activate RAGE and thereby sustain NF-κB-dependent 
gene expression. Activation of NF-κB results in increased RAGE expression and increases 
the number of ligand binding sites, thereby prolonging NF-κB activation (Schmidt et al, 2001; 
Bierhaus et al, 2001). Frequently, the biology of RAGE coincides with settings in which 
ligands of the receptor accumulate, especially in a proinflammatory environment such as 
diabetes mellitus, atherosclerosis, neurodegenerative disorders, rheumatoid arthritis, 
chronic renal disease, and inflammatory bowl disease (Basta et al, 2002; Schmidt et al, 2001; 
Lalla et al, 2001; Wendt et al, 2003; Bierhaus et al, 2004; Sakaguchi et al, 2003; Kislinger et al, 
2001; Drinda et al, 2004; Chen et al, 2004; Goosa et al, 2001). To better understand the role of 
RAGE in these pathophysiological situations, interaction of ligands with cell surface RAGE 
was intercepted using soluble RAGE (sRAGE). Soluble RAGE is a truncated form of the 
receptor comprising the extracellular domain and thereby functions as a decoy that prevents 
ligands from interacting with cell surface receptor. Application of sRAGE in vitro and in 
vivo resulted in an effective blockade of RAGE, according to a decoy mechanism, in a range 
of animal models (Hudson et al, 2003; Lue et al, 2001; Arancio et al, 2004; Constien et al, 
2001). sRAGE prevented development of micro- and macrovascular diseases in rodents, 
suggesting a key role for RAGE in the development of chronic vascular disorders. Moreover, 
sRAGE efficiently reduced late complications of experimental diabetes in both autoimmune 
(Chen et al, 2004) and streptozotocin induced diabetes (Wendt et al, 2003; Bierhaus et al,  
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2004), restored delayed wound healing (Goosa et al, 2001), protected rodent from tumor 
metastases and growth of primary tumors (Taguchi et al, 2000), and improved the outcome 
of experimental colitis (Hofmann et al, 1999). sRAGE and anti-RAGE F(ab’)2-fragments 
suppressed abnormal findings associated with Alzheimer’s-like pathology in transgenic 
rodent models (Lue et al, 2001; Arancio et al, 2004) and reduced the transport of amyloid-ǃ-
peptide across the blood-brain barrier (Mackic et al, 1998) . Since most of the data obtained 
with sRAGE were confirmed by application of neutralizing antibodies to the receptor 
and/or transfection with plasmids overexpressing dominant negative RAGE, the receptor 
has been suggested as a potentially effective therapeutic target (Hudson et al, 2003). At the 
same time, it seemed unlikely that RAGE could mediate so many deleterious effects in such 
diverse models of disease. Since RAGE has properties of a PRR, binding to a variety of 
ligands, the promising effects observed with sRAGE might not only result from intercepting 
the interaction of ligands with cell surface RAGE, but possibly with other receptors. For 
example, S100 proteins and HMGB1 certainly do not exclusively bind to RAGE. These 
ligands also recognize other cellular structures (Robinson et al, 2002; Erlandsson et al, 2004). 
In order to test the potential impact of RAGE blockade and to further define a potential role 
of RAGE in diabetic complications and chronic inflammatory disease, homozygous RAGE-
deficient mice (RAGE−/− mice) and mice with tissue-specific RAGE expression (tie2-RAGE 
and tie2-RAGE°—RAGE−/−) have been made (Constien et al, 2001). These mice are viable 
and display normal reproductive fitness without any striking phenotype (Wendt et al, 2003; 
Bierhaus et al, 2004; Sakaguchi et al, 2003). Induction of diabetes in these mice confirmed 
that RAGE contributes, at least in part, to the development of diabetic complications. 
Diabetic nephropathy, characterized by renal enlargement, glomerular hypertrophy, 
albuminuria, and mesangial expansion, was significantly increased in diabetic mice 
overexpressing RAGE in the vasculature, but was reduced in RAGE−/−mice (Yamamoto et 
al, 2001). Similar changes were observed in diabetic neuropathy. Whereas diabetic mice 
overexpressing RAGE showed an increase in functional deficits, such as delayed motor 
nerve conduction velocity (Yajima et al, 2004), RAGE−/− mice were partially protected from 
diabetes-induced loss of neural function (Bierhaus et al, 2004). Neointimal expansion in 
RAGE−/− mice was significantly suppressed compared with that observed in wildtype 
littermates using a femoral artery denudation protocol to induce arterial injury (Sakaguchi 
et al, 2003). Remarkably, in each of these models (diabetic nephropathy, neuropathy, arterial 
restenosis, etc.), protection from development of pathology was more profound in wild-type 
mice treated with sRAGE than in RAGE−/− mice. In diabetic neuropathy, for example, 
administration of sRAGE to diabetic wild-type animals completely restored pain perception, 
whereas diabetic RAGE−/− mice were only partly protected from loss of pain perception. 
These observations suggest that ligands sequestered by sRAGE are likely to interact with 
cellular structures different from RAGE and are also involved in perturbation of pain 
perception. The absence of a developmental phenotype in RAGE−/− mice and the 
possibility that RAGE might impact on multiple chronic disease states have largely focussed 
attention away from physiologic roles of the receptor. So far, only a few reports have 
suggested that RAGE expression might contribute to developmental paradigms, based on in 
vitro studies. For example, in axonal sprouting which accompanies neuronal development, 
RAGE–HMGB1 interaction may contribute (Fages et al, 2000; Hittinen et al, 2000). Huttunen 
et al. further demonstrated that activation of RAGE by HMGB1 (amphoterin) and S100B can  
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promote cell survival through increased expression of the anti-apoptotic protein Bcl-2. 
However, whereas nanomolar concentrations of S100B induced trophic effects in 
RAGEexpressing cells, micromolar concentrations caused apoptosis in a manner that 
appeared to depend on oxidant stress. For both of these outcomes, the cytoplasmic domain 
of RAGE was required, as cells expressing a dominant-negative mutant (i.e., lacking the 
cytosolic tail) are unresponsive to these stimuli. The neurite outgrowth-promoting role of 
RAGE was recently confirmed in vivo in a unilateral sciatic nerve crush model, in which 
blockade of RAGE, either by sRAGE or by blocking F(ab’)2 fragments of antibodies (raised 
to either RAGE or to S100/calgranulins or amphoterin) reduced functional regeneration of 
the peripheral nerve (Rong et al, 2004a). Similar results were observed in transgenic mice 
overexpressing dominant negative RAGE (Rong et al, 2004b). However, RAGE−/− mice 
demonstrate neither obvious neuronal deficits nor overt behavior abnormalities, indicating 
that RAGE may contribute to neuronal development, but that there are redundant systems 
that substitute for this receptor in its absence. Furthermore, it will be interesting to see if 
future experiments in RAGE−/− mice confirm a role for RAGE in the repair of peripheral 
nerve injury. In terms of a contribution for RAGE in development, expression of the receptor 
in vivo appears to mirror developmental processes. After being highly expressed during 
embryonic development, RAGE is downregulated in most organs during normal life 
(Kokkola et al, 2005). Upon aging, RAGE expression increases again, although it is not 
known whether this is due to accumulation of RAGE ligands (which upregulate receptor 
expression) or whether this represents a compensatory mechanism protecting aging cells 
from cell death. Another line of evidence for a role of RAGE in the regulation of 
differentiation comes from recently published studies showing that non-small cell lung 
carcinomas are characterized by downregulation of RAGE (Bartling et al, 2004). One reason 
for this might be that loss of HMGB1(amphoterin)/RAGE-mediated regulation of tumor cell 
migration and invasive processes results in more aggressive tumor behavior (Huttunen et al, 
2002). A COOH-terminal motif in HMGB1 (amino acids 150–183) has recently been 
identified as responsible for RAGE binding. This portion of HMGB1 efficiently inhibits 
RAGE-mediated extension of cellular processes and transendothelial migration of tumor 
cells. This observation leads us to propose that loss of RAGE might promote tumor growth, 
at least in settings affecting the lung, one of the few tissues in which RAGE is constitutively 
expressed at high levels. Since this observation contrasts with a previous finding in which 
sRAGE suppressed tumor growth and metastasis (Taguchi et al, 2000), the latter 
observations might be due to the ability of sRAGE to intercept the interaction of RAGE 
ligands with other receptors. 
8. Conclusion and prospective 
Cell death from ischemia involves a complex biological cascade. Initially, energy failure is 
followed by glutamate overload and Ca2+ influx into the cell. These processes initiate a series 
of events, including the generation of free radicals, apoptosis, an inflammatory response and 
generation of growth factors. Many of these processes are the direct result of the up- or 
downregulation of specific gene families. Thus, a desirable neuroprotectant would, in 
theory, be one that antagonises multiple injury mechanisms. The studies described above 
demonstrate an emerging role for endogenous neuroprotectant in ischemic damage and 
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ischemic prophylaxis. Among these, erythropoietin (Epo), has a dominant role for 
neuroprotection, neurogenesis and act as a neurotrophic factor in the central nervous 
system. These functions make erythropoietin a good candidate for treating disease 
associated with neuronal cell death. However, our understanding of the underlying 
mechanisms is far from being complete and a number of open questions remain to be 
answered: 1) What is the exact route and mechanism through which Epo passes through the 
BBB? 2) Which cellular mechanisms govern the immunomodulatory effects of Epo in glial 
cells? 3) Does Epo activate the same or diverse intracellular signaling pathways in the 
different cells that express EpoR in the brain, neurons, glial, and endothelial cells? 
Nevertheless, since the discovery of Epo expression in the brain less than 15 years ago, a 
tremendous achievement in the understanding of its action in the CNS has been 
accomplished. Today, Epo is a prominent member of a growing list of hematopoietic and 
angiogenic factors found to be expressed and acting as protective factors in the CNS. 
Because of the observed increased death rate, rtPA-treated patients should be excluded from 
acute poststroke EPO application. In cerebral ischemia, albumin is mainly involved in the 
improvement of blood microcirculation; however, direct neuroprotection cannot be 
overlooked. Different in vitro and in vivo studies indicate that albumin has direct 
neuroprotective effects by acting on astrocytes, microglia and neurons. Altogether albumin 
can alter brain function by many direct and indirect mechanisms and detailed study of these 
actions will reveal the role of this multifunctional protein in brain functions. Furthermore, 
the evidence of de novo synthesis of albumin in microglial cells could encourage the 
neurologist to investigate newer roles of this multifunctional protein in many 
neurodegenerative diseases. The prothrombotic, proinflammatory state of stroke results in a 
promotion of thrombin formation and fibrin deposition at the vascular wall, as well as in the 
formation of platelet-leukocyte coaggregates, leading to severe disturbance of the 
microcirculation, capillary leakage and tissue damage. The ability of ATIII to inhibit the 
actions of both factor Xa and thrombin gives it the potential to block, in part or fully, a wide 
rage of proinflammatory events. Heparin and heparan sulfate glycoproteins (HSPGs) appear 
to function as receptors for ATIII on endothelium and leukocytes and can lead to the 
reduced expression of procoagulatory tissue factor and proinflammatory cytokines as well 
as heterologous receptor regulatory processes. ATIII has been shown in vitro to increase 
prostacyclin responses and to inhibit a variety of cell responses including endotoxin-
induced nuclear translocation of NF-kB, a key step in the generation of the inflammatory 
response. 
Here, we also discussed the critical role of Toll-like receptors in mediating cerebral ischemic 
injury and suggested endogenous mechanisms that, when induced, redirect this role from 
detrimental to beneficial. In fact, many diverse neuroprotective paradigms may redirect TLR 
signaling as one mechanism of endogenous protection. Paradoxically, TLR ligands 
administered systemically induce a state of tolerance to subsequent ischemic injury. Herein 
we suggest that stimulation of TLRs prior to ischemia reprograms TLR signaling that occurs 
following ischemic injury. Such reprogramming leads to suppressed expression of pro-
inflammatory molecules and enhanced expression of numerous anti-inflammatory 
mediators that collectively confer robust neuroprotection. Research findings indicate that 
numerous preconditioning stimuli lead to TLR activation, an event that occurs prior to 
ischemia and ultimately leads to TLR reprogramming. Thus genomic reprogramming of 
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TLR signaling may be a unifying principle of tolerance to cerebral ischemia. Recent studies 
have also demonstrated an increased expression of the cell-surface RAGE in dying neurons 
after hypoxic-ischemic insults and human cerebral ischemia, and suggested that the RAGE-
ligand interaction causes neuronal cytotoxicity. RAGE also has a circulating truncated 
variant isoform, soluble RAGE (sRAGE), which corresponds to its extracellular domain 
only. Exogenously administered sRAGE has been successfully used to antagonize advanced 
glycation end products (AGE)-RAGE-mediated vascular damage. Accordingly, sRAGE may 
compete with cell-surface RAGE for the ligand, thus functioning as a decoy and possibly 
exerting a cytoprotective effect. Most of the data available so far point to the RAGE/NF-κB 
axis as an attractive target for future clinical interventions in several chronic disease states. 
However, until physiologic properties of RAGE have been clearly deciphered, it is most 
prudent to adopt a cautious approach when future therapeutic strategies involving long-
term blockade of RAGE or its ligands are considered. Another important issue to be 
addressed concerns how studies performed in rodent models will translate to human 
disease. Alternatively, if RAGE antagonists are eventually used in humans, it will be 
fascinating to understand the impact of long-term blockade of RAGE in critically ill patients, 
in view of the likely complex role of RAGE, and other receptors interacting with RAGE 
ligands, in regulating physiologic and pathophysiologic processes in a wide range of 
situations. 
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